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Abstract 
In Sudan as in many other countries the emerging drug resistant tuberculosis is causing a major public 
health threat. In the present study 250 sputum samples randomly collected from new tuberculosis 
patients were collected before administration of drugs from patients of different age groups of both 
sexes. The patients were from Khartoum Teaching Chest Hospital and Hamed El-Nile Hospital. The 
samples were collected during the period July 99 to May 2000. All studied patients were clinically 
diagnosed as tuberculosis cases. The samples were collected to study the primary drug resistance 
mutation in M. tuberculosis complex.  
201 out of the 250 samples (80.5%) were found to have acid fast bacilli (AFB) on microscopy. 147 out 
of the 201 AFB positive (73.1%) gave growth of M. tuberculosis complex on Löwenstein Jensen 
medium (LJ) and three (6.1%) out of 41 which were not (AFB). 17 of the isolates (8.5%) were rapid 
grower mycobacteria other than tuberculosis (MOTT). Seven (3.5 %) were Nocardia sp. which were 
fully identified using biochemical test and molecular methods such as sequencing. The species was 
discovered to be a new entity and given a new name (Nocardia africana) by the International 
Taxonomy for bacteria, and 14 (6.9%) of the samples shown were contaminated cultures and 16 (7.9%) 
of the samples did not show any growth. 
The polymerase chain reaction (PCR), amplification of IS6110 and the Restriction Fragment Length 
polymorphism (RFLP)-fingerprinting using PVUII enzyme was used to confirm the above phenotypic 
identify of the mycobacteria, using these techniques, 150 isolates were found to be M. tuberculosis 
complex.  
DNA from all the 150 M. tuberculosis isolates was extracted and then amplified by PCR using specific 
primers (TR8, TR9) to amplify rpoB gene around codon 43. Mutation in this gene is known to confer 
resistance to rifampicin. Single Strand Conformation Polymorphism (SSCP) technique was used to 
detect the presence of mutations among the 150 M. tuberculosis strains.  Only four strains showed 
mobility shift due to rpoB mutant gene. This is indicative of primary drug resistance to rifampicin. 
The analysis of rpsL gene around codon 43 by PCR- RFLP to the 150 M. tuberculosis strains revealed 
that only two isolates of M. tuberculosis did not cut with the restriction enzyme MboII. This indicates 
that these two strains have mutation at the rpsL gene which is responsible for resistance to 
streptomycin.   
  V
The rate of primary mutation among the 150 M. tuberculosis strains isolated from new tuberculosis 
(received no treatment) was thus found to be 2.7 %, 1.33 % for rpoB and rpsL genes, respectively. And 
the rate of both genes was found to be (0.7%). 
 
      
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV  
  ﻤﻠﺨﺺاﻟ
ﻓـﻰ اﻟـﺴﻮدان آﻤـﺎ ﻓـﻰ اﻟﻌﺪﻳـﺪ ﻣـﻦ اﻟـﺪول اﻻﺧـﺮى اﺻـﺒﺤﺖ ﻣـﺸﻜﻠﻪ ﻣﻘﺎوﻣـﺔ 
  (sisolucrebut .M )ﻋﺼﻴﺎت اﻟﺴﻞ
 اﻟﻤـﺮض ﺗـﺸﻜﻞ ﺗﻬﺪﻳـﺪا رﺋﻴـﺴﻴﺎ ﻟﻠـﺼﺤﻪ ﻋـﻼج اﻟﺮﺋﻮىﻠﻠﻌﻘﺎﻗﻴﺮ اﻟﻤﺴﺘﺨﺪﻣﻪ ﻓﻰ 
  .اﻟﻌﺎﻣﻪ
 ﻋﺸﻮاﺋﻴﺎ ﻣﻦ ﺣـﺎﻻت ﺣﺪﻳﺜـﻪ ﻟﻤﺮﺿـﻰ  ﺑﻠﻐﻢ  ﻋﻴﻨﻪ 052ﻓﻰ هﺬﻩ اﻟﺪراﺳﻪ ﺗﻢ اﺧﺬ 
، اﺧﺬت اﻟﻌﻴﻨـﺎت ﻣـﻦ  ﻚ ﻗﺒﻞ اﻟﺒﺪء ﻓﻰ ﺗﻌﺎﻃﻰ اﻟﻌﻼج ﻣﺼﺎﺑﻴﻦ ﺑﺎﻟﺘﺪرن اﻟﺮﺋﻮى وذﻟ 
 اﻟﻤﺮﺿﻰ اﻟﻤﺘﺮددﻳﻦ ﺗﻢ ﺟﻤﻊ اﻟﻌﻴﻨﺎت ﻣﻦ . اﻋﻤﺎر ﻣﺨﺘﻠﻔﻪ ﺑﻐﺾ اﻟﻨﻈﺮ ﻋﻦ اﻟﺠﻨﺲ 
 ﻟﻠـﺼﺪر وذﻟـﻚ ﻓـﻰ  ﻣﺴﺘﺸﻔﻰ اﻟﺨﺮﻃﻮم اﻟﺘﻌﻠﻴﻤﻰ وﻣﺴﺘـﺸﻔﻰ ﺣﻤـﺪاﻟﻨﻴﻞ ﻓﻰ
م وذﻟﻚ ﺑﻐﺮض دراﺳـﺔ  ﻣﻘﺎوﻣـﺔ ﻋـﺼﻴﺎت 0002 وﺣﺘﻰ ﻣﺎﻳﻮ 9991اﻟﻔﺘﺮﻩ ﻣﻦ ﻳﻮﻟﻴﻮ 
  .اﻟﺴﻞ اﻟﺮﺋﻮى ﻟﻠﻌﻼج
 وﺑﻌـﺪ   اﻟﻠﻄﺎﺧﻪ ﻟﻠﻌﺼﻴﺎت اﻟﺪرﻧﻴـﻪ ﻣﻮﺟﺒﺔ ﻣﻨﻬﺎ 102 ﻋﻴﻨﻪ وﺟﺪ ان 052ﻣﻦ ﻣﺠﻤﻞ 
ذﻟﻚ ﺗﻢ اﻻﺳﺘﻨﺒﺎط اﻟﺰراﻋﻰ اﻟﻘﻴﺎﺳﻰ ﻟﻬـﺎ ﻓـﻰ ﻣـﺴﺘﻨﺒﺖ  ﻟﻮﻳﻨـﺴﺘﺎن ﺟﻮﻧـﺴﻮن  
 ﻋﺘﺮﻩ ﻣﺘﻔﻄـﺮﻩ 741ﺣﻴﺚ وﺟﺪ ﻣﻦ ﻣﺠﻤﻞ ﻟﻠﻄﺎﺧﺎت اﻟﻤﻮﺟﺒﻪ ﻟﻠﻌﺼﻴﺎت اﻟﺪرﻧﻴﻪ ان 
 اﻟﻠﻄﺎﺧﻪ ﻟﻠﻌﺼﻴﺎت ﺑﺎﻻﺿﺎﻓﺔ اﻟﻰ ﺛﻼث ﻋﺘﺮات ﻣﻦ اﻟﻌﺘﺮات اﻟﺴﺎﺑﺔ (%1.37)ﺳﻠﻴﻪ 
( %5.3) ﻋﻴﻨﺎت 7 و %(5.8)ﺳﺮﻳﻌﻪ اﻟﻨﻤﻮ ﻣﺘﻔﻄﺮﻩ ﻏﻴﺮ ﻣﺘﺪرﻧﻪ    ﻋﺘﺮﻩ 71 و اﻟﺪرﻧﻴﻪ
  اﻟﻤﻴﻜﺮوﺑﻴـﻪ اﻟﺘﻤﻴﻴﺰﻳـﺔ اﻟﺘﺤﻠﻴـﻞ  وﺟﺪ اﻧﻬﺎ ﻣﻦ ﺟﻨﺲ اﻟﻨﻮآﺎردﻳﺎ وﺑﺎﺟﺮاء ﻣﺰﻳـﺪ ﻣـﻦ 
 اﻟـﻰ  ﺑﻮاﺳـﻄﻪ اﻟﺘـﺼﻨﻴﻒ اﻟﻌـﺎﻟﻤﻰ ﻟﻠﺒﻜﺘﻴﺮﻳـﺎ  وﺗﻤﺖ اﺿـﺎﻓﺘﻪ ﻓﺼﻴﻞ ﺟﺪﺑﺪ وﺟﺪ اﻧﻪ 
  ﻋﻴﻨـﻪ ﺣـﺪث ﻟﻬـﺎ ﺗﻠـﻮث ( 9.6)%41دﻳـﺎ اﻓﺮﻳﻜﺎﻧـﺎ و ﻋﺎﺋﻠﻪ اﻟﻨﻮآﺎردﻳـﺎ وﺳـﻤﻰ ﺑﻨﻮآﺎر 
ﺗــﻢ اﺳــﺘﺨﺪام ﻃﺮﻳﻘــﻪ اﻟﺘﻔﺎﻋــﻞ  .اﻟﻨﻤــﻮ  ﻋﻴﻨــﻪ آﺎﻧــﺖ ﺳــﺎﻟﺒﻪ %(9.7)61ﺑﻴﻨﻤــﺎ 
( اﻟﺒ ــﺼﻤﻪ) اﻟﺘﺤ ــﻮﻳﺮ اﻟﺘﻤﻴﻤــﻰ اﻟﻄــﻮﻟﻰ ﻟﻠﻘﻄــﻊ – (RCP)اﻟﺴﻠ ــﺴﻠﻰ اﻟﻤﺘﺒﻠﻤ ــﺮ 
وذﻟـﻚ ﻟﺘﺎآﻴـﺪ ﻧﺘـﺎﺋﺞ ( 011S61)واﻟﻌﻨـﺼﺮ اﻟﻤـﺪﺧﻞ ( II UVP) ﺑﺎﺳـﺘﺨﺪام  اﻻﻧـﺰﻳﻢ 
 وﻟﻘـﺪ ﻣﺘﻔﻄـﺮﻩ ﺳـﻠﻴﻪ ﻋﻴﻨـﻪ  اﻟﺘـﻰ وﺟـﺪت 051ﺎهﺮى ﻟـﻞ اﺧﺘﺒـﺎرات اﻟـﻨﻤﻂ اﻟﻈـ
IIV  
 ﺗـﻢ اﺳـﺘﺨﻼص ﺴﻠﻴﻪ اﻟ ـﻔﻄﺮﻩآﻞ اﻟﻌﺘﺮات اﻟﻤﺘ .ﺗﻄﺎﺑﻘﺖ ﻣﻊ ﻧﺘﺎﺋﺞ اﻟﻨﻤﻂ اﻟﻈﺎهﺮى 
(    RCP) ﺑﺎﺳـﺘﺨﺪام Boprوﻣـﻦ ﺛـﻢ اﺳﺘﻨـﺴﺎخ ﺟﻴﻨـﺎت ( AND)ﺣﻤـﻀﻬﺎ اﻟﻨـﻮوى 
  9RT  و  8RT( remirp)اﻟﺘﻔﺎﻋﻞ اﻟﺴﻠﺴﻠﻰ اﻟﻤﺘﺒﻠﻤﺮ ﺑﺎﺳﺘﺨﺪام اﻟﺒـﺎدى اﻟﺨـﺎص 
ارﺑﻌـﻪ ﻋﺘـﺮات ( PCSS)  وﺗﻘﻨﻴﻪ اﻟﺘﺤﻮﻳﺮ اﻟﺘﺎآﻴﺪى ﻟﻠﺨﻴﻂ اﻻﺣﺎدى 34ﺣﻮل اﻟﻜﻮدون 
    ﺴﻠﻴﻪاﻟﻤﺘﻔﻄﺮﻩ ﻣﻦ ﻣﺠﻤﻞ اﻟﻌﺘﺮات اﻟ%( 7.2)ﻓﻘﻂ
وهﺬا ﻳﻌﻨـﻰ اﻧﻬـﺎ ﻣﻘﺎوﻣـﻪ ﺑـﺪاﺋﻴﺎ ﻟﻌﻘـﺎر ( Bopr)  اﻇﻬﺮت اﻟﺤﺮآﻪ اﻟﺘﺒﺎدﻟﻴﻪ ﻟﻠﻄﺎﻓﺮ 
  .اﻟﺮﻳﻔﺎﻣﺒﺴﻴﻦ
 اﻟﻤـﺴﺌﻮل ﻋـﻦ اﻟﻤﻘﺎوﻣـﻪ )88ﺣـﻮل اﻟﻜـﻮدون ( Lspr)  اﻟﺘﺤﻠﻴـﻞ اﻟﺠﻴﻨـﻰ ﻟﻠﺠـﻴﻦ 
ﺗﻢ اﻟﺘﺤﻠﻴﻞ ﺑﺎﺳﺘﺨﺪام ﺗﻘﻨﻴﺔ اﻟﺘﻤـﻴﻢ اﻟﻘﻄﻌـﻰ ﻟﻠﺘﻔﺎﻋـﻞ ( ﻟﻌﻘﺎر اﻻﺳﺘﺮﺑﺘﻮﻣﺎﺳﻴﻦ 
ﻣـﻦ  ﻣﺠﻤـﻞ %( 3.1)وﺟﺪ ان هﻨﺎﻟﻚ ﻋﺘﺮﺗﻴﻦ ﻓﻘﻂ ( PLFR)اﻟﺘﺴﻠﺴﻠﻰ اﻟﻤﺘﻌﺪد 
 ﻟـﻢ ﻳﺤـﺪث ﻟﻬـﺎ ﻗﻄـﻊ اﻧﺰﻳﻤـﻰ وﺑﺎﻟﺘـﺎﻟﻰ ﻓﻬـﻰ ﺗﺤـﻮى ﺴﻠﻴﻪاﻟ ـﻤﺘﻔﻄﺮﻩ اﻟﻌﺘﺮات اﻟ 
ﻟﻄﻔـﺮة اﻻﺑﺘﺪاﺋﻴـﻪ ﻣﻌـﺪل ا .اﻟﻤﻘﺎوم ﻟﻌﻘﺎر اﻻﺳﺘﺮﺑﺘﻮﻣﺎﺳـﻴﻦ ( Lspr)اﻟﻄﺎﻓﺮ اﻟﺠﻴﻨﻰ 
  Lspr و Boprﻟﻠﻄـﺎﻓﺮﻳﻦ  % 33.1و% 7.2 وﺟـﺪ ﺳـﻠﻴﻪ  ﺘﻔﻄـﺮﻩ ﻋﺘـﺮﻩ ﻣ 051ﺑﻴﻦ ال 
  %.7.0آﻤﺎ وﺟﺪ ان اﻟﻤﻌﺪل ﻟﻠﻄﺎﻓﺮﻳﻦ ﻣﻌﺎ . ﻋﻠﻰ  اﻟﺘﻮاﻟﻰ
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CHAPTER ONE 
 
INTRODUCTION AND OBJECTIVES 
 
 Today tuberculosis is a major cause of morbidity and mortality (8 millions new cases annually) in the 
world particularly in developing countries. More than one billion individuals are infected with M. 
tuberculosis and more than 3.5 million people die per annum worldwide (Avachee et al. 1999; Hass 
and Des Prez 1995). The epidemiology of the illness is changing in relation to HIV infection epidemic, 
socioeconomic problems and emergence of drug-resistant strains (Sudre et al., 1992; Centre for 
Disease Control, 1993; Cohn et al., 1997). Despite the availability of effective chemotherapies, 
tuberculosis is responsible for one in four avoidable adult deaths in developing countries (Nolte and 
Mitchock, 1995). 
 
 There is an increasing number of tuberculosis cases and outbreaks of   multidrug-resistant tuberculosis 
strains (MDR) over the past few years, Therefore has been a resurgence of interest in rapid diagnostic 
of M. tuberculosis infection (Nolte and Mitchock, 1995). The delay of the diagnosis of the tuberculosis 
not only delays the treatment of the patients but may lead to increasing the spread of disease and MDR 
strains (Musser, 1995). The worldwide resurgence of tuberculosis has prompted the development of 
new (molecular) techniques to classify the bacillus, which have advanced the understanding of the 
transmission of the disease (Musser, 1995).  
 
  Infection with drug sensitive strains of M. tuberculosis can be effectively cured with combination of 
isoniazid (INH), rifampicin (RIF) and pyrazinamide (Combs, et al., 1990). However, the particular 
susceptibility and increased mortality of the disease among individuals infected with human 
immunodeficiency virus (HIV) pose a serious threat to tuberculosis control programs (Perrins, 1991). 
Moreover, the emergence of multi-drug resistant strains of M. tuberculosis (MDR-TB) has resulted in 
fatal outbreaks in many countries, including the Unite States (Snider and Robert, 1992).  
 
According to WHO/IUALTD, 63 survey of resistance to antituberculous drugs have been performed 
between 1985 and 1994. Rates of primary resistance to isoniazid administered as single agent ranged 
from 0 to 16.9% (median rate, 4.1%)  to streptomycin 0.1-23.5%  (median rate, 3.5%)  to rifampicin 0.-
3.0%  (median rate, 0.2%) and to ethambutol 0. –4.2% (median rate, 0.1%). The rates of acquired 
resistance were higher than those of primary resistance, which were as follows: isoniazid 4.0-53.7% 
(median rate, 10.6%) to streptomycin 0. –19.4% (median rate, 4.9%) to rifampicin 0.-14.5% (median 
rate, 2.4%) and to ethambutol 0. –13.7% (median rate, 1.8%). The highest rates of MDR-TB have been 
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reported in Nepal (48.0%), Gujarat, India (33.8 %), New York City (30.1 %), Bolivia (15.3 %) and 
Korea (14.5 %). 
 
According to WHO/IUALTD a previous survey of drug resistance from 35 countries, the weighed 
mean of primary resistance to any drug ranged from 2 % to 41 % and the acquired resistance to any 
drug from 5.3 % to 100 % (WHO, 1997).  
 
By the end of second quarter of the 1998 the total number of tuberculosis cases in the Sudan was 
82860, according to the Sudan National Tuberculosis Program (Elsony et al, 2000). Sharaf Eldin 
(2001) found that the acquired resistance to streptomycin was 30 % (20 % rpsL gene and 10 % rrs 
gene) and to rifampicin was 8% (rpoB gene) and to isoniazid was 12 % (Kat G gene) and for 
ethambutol was 4 %( embB gene) and 4 % had mutations in genes associated to both INH and RIF in 
Khartoum state. 
 
Objectives 
The main objective 
To detect the primary drug resistance in rpoB gene associated with rifampicin and in rpsL gene      
associated with streptomycin among new tuberculosis patients in Khartoum State. 
 
Other  objectives of this study  
To use  molecular methods as rapid and reliably to detecting of M. tuberculosis.  
To estimate the rate of resistant strains of M. tuberculosis in Khartoum State.  
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
1. Tuberculosis 
1.1 Tuberculosis; The early days 
 
Tuberculosis is one of the most prevalent infectious diseases of mankind, and is a leading cause of 
mortality as a single infectious agent worldwide (Bloom, 1992). Tuberculosis remains one of the most 
important infectious diseases in the world socio-economically, particularly in parts of Asia and India 
and Africa (Bloom, 1992).  
 
Tuberculosis was known in antiquity, for it is ravages can be recognized in lesions of bones that have 
survived. Probably the first known example of disease of the vertebral column dates for the Neolithic 
period (about 5000 BC). There is evidence of bony lesions in Egyptian mummies and the disease may 
have been common in the predynastic period of Egypt (Florey, 1961). A clay statuette dating from 
about 4000 BC shows the distortion of the spine often associated with tuberculosis (Sigerist, 1951). It 
does not seem that tuberculosis of the lungs was common in Egypt, for no description of this form of 
the disease exists, but Phthisis was recognized by the Greeks, and described in the Hippocratic writing 
(ca.400 BC). Tuberculosis of lungs was also mentioned in the Indian Rig-Veda (about 1500 BC), and 
there were a number of representation of the disease among the primitive statuettes of the New World. 
The idea of tuberculosis as a separate disease did not emerge until 1671 when Francis Sylvius (De le 
Boe) used the term tubercular minoravel majora to describe the appearances of lesions of the lungs. 
Very accurate description of the macroscopic appearances of tubercles lesions were given by William 
Stark (1740-1770), whose work appeared in 1788, and by Matthew Baillie (1761-1823), who published 
his observations in 1793 (Florey, 1961). 
  
Mycobacterium has caused disease in humans since recorded history began; lesions clearly caused by 
mycobacteria have been identified in Egyptian mummies related to the Corynebacteria and to 
Nocardia species. The mycobacteria contain several pathogenic species to humans as well as those 
pathogenic to animals and fish. Mycobacterium tuberculosis is found only in human, its infectious 
nature was suspected by Fracastorius in the early part of the sixteenth century.  
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In 1865 Villimen showed that the disease could be transmitted by the inoculation of tubercles material. 
It was in 1882 that Koch demonstrated the tubercle bacillus by special staining isolated and grew it in 
pure culture, and reproduced the disease by the inoculation with the bacilli (Burrow, et al, 1995).  
 
 Robert Koch was the first to establish the causal relationship between the tubercle and tuberculosis. 
The organism was named Mycobacterium tuberculosis in 1886, presumably because it resembled a 
fungus in its slow growth and colony morphology (Patrick and Ellen., 1995).  
  
One hundred years after Robert Koch's discovery of the tubercle bacillus, tuberculosis is still the most 
important specific communicable disease in the world. It is estimated that eight million new cases of 
tuberculosis appear each year in developing countries and at least three million persons die of the 
disease, in the technically advanced countries the incidence much less than this (WHO 1996). 
 
1.2 Definition  
 
Tuberculosis is a chronic infectious disease of lungs and it can affect every organ system, it is clinical 
manifestations are fatigue, weakness, weight loss and fever. Pulmonary involvement giving rise to 
chronic cough and spitting of blood is usually associated with far - advance lesion, Meningitis or 
urinary tract involvement can occur in the absence of other signs of tuberculosis. Blood stream 
dissemination leads to miliary tuberculosis with lesion in many organs and high mortality rate ((Walter 
and Israel, 1987) 
Tuberculosis affects mammalian, avian, and cold-blooded animals. Mammalian tuberculosis is divided 
into human, bovine and vole types, the human variety is partially always responsible for pulmonary 
tuberculosis in adult, and usually the bovine variety may occur occasionally in the pulmonary form 
(Powel, et al. 1980). 
Tuberculosis in human caused by Mycobacterium tuberculosis complex, which includes M. 
tuberculosis, M. bovis, M. africanum, and M. microti.  
 
1.3 Methods of the diagnosis of TB 
There are many methods to diagnose a patient as TB patient and it s usually done as follow; 
 
1.3.1 Clinical diagnosis 
Clinically TB diagnosis is based on characteristic symptom such as; fatigue, weakness, weight loss and 
fever may be signs of tuberculosis disease. Pulmonary involvement giving rise to chronic cough and 
spitting of blood usually is associated with far- advance lesion (WHO, 1998). 
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1.3.2 X - Rays 
Chest x-ray it is one of the most important methods of diagnosis of pulmonary tuberculosis (WHO, 
1998). 
 
1.3.3Tuberculin test 
 
Tuberculin skin test which consists of injection of purified protein derivative intra  dermal, is used to 
identify individuals with tuberculosis disease (WHO, 1998). 
 
1.3.4 Microscopic examination 
 
Ziehl Neelson (ZN) or Kinyoun or flurochrome dyes are used to stain the Mycobacterium and then 
examined under microscopy, ZN stain is rapid and low cost, but low sensitivity (Yeager et al, 1967). 
ZN stain recommended by WHO to be used for tuberculosis microscopy is use to diagnosis TB (WHO, 
1998) 
 
1.3.5 Culture methods 
 
Löwenstein-Jensen medium (LJ) is used for tuberculosis culture, LJ with glycerol used for the growth 
of M. tuberculosis and with pyruvate for M. bovis (WHO, 1998)  
 
1.3.6 Serological test 
 
The Serological test method is used to detect M. tuberculosis antigens, this test depend on antigens and 
antibodies reaction, It is measurement of IgG antibody, with specific antigens in an ELISA test (WHO, 
1998) 
 
1.3.7 Molecular methods 
 
There are many molecular methods to diagnosis of TB targeting the nucleic acids such as; PCR and 
sequencing. 
 
1.3.7.1 Polymerase Chain Reaction (PCR) 
 
 PCR is an in vitro nucleic acid amplification method. The reaction comprises repeated thermal cycling 
of the reaction mixture .the thermal cycling serves to dissociate the products of the previous thermal 
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cycle then allow the association of these dissociated oligonucleotide strand from the previous thermal 
cycle, products with further reaction starting materials for another phase of synthesis. (Saiki et al, 1985 
and 1988). Specifically, substrate DNA is denatured at a high temperature to give single-stranded 
(template) molecules. This is followed by short oligonucleotide primers (amplimers) annealing to 
specific, nucleotide-sequence-defined regions of the template at a lower temperature. The positions 
where the amplimers anneal to the template define the (target) the thermal cycle is concluded by the 
amplimers being enzymatically extended by the coupling of appropriately base-paired deoxynucleoside 
triphosphates (dNTPs) on the template at an intermediate temperature, thus producing another double-
stranded DNA (ds DNA) copy of the original target.  (Saiki et al, 1985). 
 
1.3.7.2 PCR-Gene specific 
 
PCR-Gene specific it is specific sequences; dnaJ gene (Takewaki et al., 1993 and 1994) Genus- 
specific targets such as 65-Kda heat shock protein gene (Telenti et al., 1993) and ribosomal DNA genes 
have been used for this purpose (Vaneechoutte et al. 1993). The PCR- dnaJ gene recognizes the broad 
spectrum of mycobacterial species (Syun et al., 1993) 
 
1.3.7.3 DNA fingerprinting designated 1S6110 
 
It was first reported by Thierry et al., (1990) is usually used to identify M. tuberculosis complex. This 
ability to accurately identify related strains of M. tuberculosis complex can help to define the people 
and places involved in M. tuberculosis transmission. Tuberculosis control personnel can use this 
information to design and implement more effective TB control measures. M. tuberculosis DNA 
fingerprinting is based on small piece of repitive DNA, named 1S6110, that may be present from 1 to 
20 or more  times in the M. tuberculosis genome 
 
 1.3.7.4 Sequencing 
The 16S-rDNA is the target used to this method (Jonas et al., 1993; Van der Vliet et al., 1993), the 
attractive feature of this molecule is that contains conserved gene specific as well as various specific 
regions. Therefore, it was straight forward to use this molecule or the gene coding 16S rRNA as a 
powerful target for amplification of mycobacteria to both genus and species level (Kox et al., 1995; 
Van der Vliet et al., 1993),   this strategy is applicable to an other target in the RNA, particulary the 
23S RNA (Shah et al, 1995) or 23S-16SrDNA spacer (Frothingham and Wilson, 1993; Glennon et al, 
1994) 
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1.4 Pathology 
1.4.1 Pathogenesis of the tubercles lesion  
The following sequence of events occur when tubercle bacilli are introduced into the tissue.  
Transient acute inflammatory reaction with an infiltration of polymorphs. These cells are rapidly 
destroyed by the organisms. A progressive infiltration of macrophages derived mostly from the 
monocytes of the blood. The macrophages are responsible for the destruction of the organisms. The 
macrophages phagocytose the bacilli. In a short time their character changes: their cytoplasm become 
pale and eosinophilic and their nuclei elongated and vesicular. Their appearance bears a resemblance to 
the epithelial cell, and they are called epithelioid cells. Some macrophages, instead of becoming 
epithelioid cells fuse to form langhan's giant cells. surrounding this mass of altered macrophages there 
is a wide zone of small round cells, mostly lymphocytes and fibroblasts. (Walter and Israel, 1987) 
 
Within 10 to 14 days necrosis begins in the center of this mass, which consists of altered macrophages 
and cells, peculiar to the tissue of the part. This is a firm, coagulative necrosis called caseation, and it is 
characterized by a high content of lipid and a tendency to resist autolysis and demolition. Histologically 
the necrosis is less structure and eosinophilic, but with silver stains reticulum fibers can sometimes be 
demonstrated. (Walter and Israel, 1987) 
 
The caseation is due primerly to hypersensitivity to products of the bacilli and notable tuberculo-
protein. Ischaemia plays some part also, in as much as the blood supply become inadequate for the 
heavy infiltration of cells into the affected area, this produced the tubercle follicle which consist of 
central mass of caseation surrounded by epithelioid and giant cell, which in turn are enclosed in wide 
zone of small round cells. The appearance is characteristic of tuberculosis, but a rather similar picture is 
seen in some of the deep-seated mycoses. This is a common type of lesion of tuberculosis and is called 
productive or proliferative, because its main components are cells rather than fluid exudates. Another 
type of lesion is the exudative form of tuberculosis which is characterized by the out-pouring of an 
inflammatory exudate rich in fiber. There is a considerable infiltration of lymphocytes, and often 
polymorphs are present, but epithelioid and giant cells are rather scanty. Exudative lesion is typical of 
tuberculosis of serous cavities. (Walter and Israel, 1987). 
 
1.4.2 Distribution of lesions in the body 
The principles differ in no significant way from those of other infections. Local spread by macrophages 
has been as fellows, progressive infiltration of macrophages derived mostly from the monocytes of the 
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blood. The macrophages are responsible for the destruction of the organisms. (Walter & Israel, 1987). 
Lymphatic spread is a continuation of local spread. The result is a regional tubercles lymphadenitis 
which is typical of childhood infection .The primary focus with its attendant lymphangitis is called the 
primary complex. Now a day nearly all primary complexes are pulmonary (Walter & Israel, 1987). 
 
Blood spread occurs as an extension of lymphatic involvement, in an over whelming infection. The 
organisms escapes from the lymph nodes and enters the blood stream to produce miliary tuberculosis, 
which in extreme cases is of the non-reactive type. The lungs, spleen, liver, kidney, and to a lesser 
extent other organs, are seeded with tubercle bacilli which produce numerous follicles of millet-seed 
size lessions. Blood spread also occurs when caseous hilar nodes directly implicate an adjacent 
pulmonary vein. If there is a discharge of large numbers of organisms into the blood stream, miliary 
tuberculosis occurs, but the lungs are relatively spared. Spread in serous cavities is seen in the pleurisy 
that may complicate lung lesion, the localized peritonitis found around tubercles salpingitis, and in 
tubercles meningitis. (Walter & Israel, 1987) 
 
Spread along epithelial-lined surfaces is typified by the inter-bronchial spread of tuberculosis that 
occurs when sputum inhaled into adjacent lung segments. If the sputum is coughed up it can produce 
tubercles laryngitis, and when swallowed, the bacilli may infect the ileo-caecal area of the bowel and 
lead to tubercles enteritis. Rectal involvement is manifested by ischiorectal abscesses. Like-wise 
tuberculosis of the kidney can spread down the ureter to implicate the trigone of the bladder.  
Tuberculosis of the skin and bone e.g. Pot's disease. (Walter & Israel, 1987)     
          
1.5 Epidemiological aspects: 
 1.5.1. Transmission and Sources of infection 
Pulmonary tuberculosis infection is usually by respiratory droplets, discharged on coughing by person 
with infectious pulmonary lesion. It may also result from the swallowing of organisms from hands or 
feeding utensils contaminated by infected person. Indiscriminate spitting can contribute to transmission 
since sputum from infected person often contains infectious bacilli (Sepkowitz et al, 1995). Non-
pulmonary infection caused by M. bovis usually resulted from the drinking of milk from infected cows 
or through contact with infected cattle, but in the tropics most non-pulmonary tuberculosis is caused by 
M. tuberculosis (Woods, 1993) 
1.5.2. Distribution of tuberculosis 
Tuberculosis (TB) called the captain of all the infectious diseases that have plagued man (Doubs, et 
al.1952). Tuberculosis is the most significant single infectious cause of morbidity and mortality, 
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producing eight million new cases and killing three million people annually. It causes approximately 
one quarter of all avoidable adult death from infection. (Raviglione et al. 1995, Murray et al 1990 and 
WHO 1996) 
 
1.5.2.1. Distribution of tuberculosis in the world:  
 
 During this period (1990-2000) it was estimated that 88.2 million people will develop tuberculosis, 8.0 
million of which will be attributable to HIV infection. In South East Asia, 35.1 million new cases of 
tuberculosis were expected during the decade, including 2.8 million (8%) HIV - attributable cases. 
Around 20.5 million new cases were predicted for the Western Pacific region, including 0.4 million 
(2%) HIV attributable cases, while 15.0 million cases were expected in Sub-Saharan Africa during the 
decade, including 3.9million (25%) cases attributable to HIV infection.  During these ten years it was 
estimated that 30.0 million people will die of tuberculosis; 2.9 million of these deaths (9.7%) will be 
attributable to HIV infection. In South -East, 12. 3 million tuberculosis deaths may occur during the 
decade, including 1.0 million HIV attributable deaths. Around 6.0 million tuberculosis deaths were 
expected in Sub -Saharan Africa, 1.5 million (25%) of which will be attributable to HIV infection (Fig. 
1) (WHO, 1997).  
 
The WHO global tuberculosis programme joined forces with International Union Against Tuberculosis 
and Lung Disease (IUATLD) and started the global project on anti- tuberculosis drug resistance 
surveillance including 35 countries and approximately 50,000 tuberculosis cases. Testing for resistance 
to EMB, STR and INH, the mean findings; the prevalence of primary drug resistance to any drug 
ranged from 2% (Czech Republic) to 41% (Dominican Republic), with a medium value of 10.4%. 
 
 Primary resistance to all 4 drugs tested was found in a medium of 0.2% of the case (rang 0 to 4.6%). 
Primary MDR-TB was found in every country surveyed except Kenya, with medium prevalence of 
1.4% (rang 0 Kenya to 14.4% Latvia). 
  
The prevalence of acquired resistance to any drug ranged from 5.3% (New Zealand) to 100% (Ivanovo 
Oblast, Russia) with median of 4.4% of cases rang (from 0 to 17%) . The median prevalence of 
acquired MDR-TB was 13% with a range from 0% (Kenya) to 54%(Latvia) with median of 4.4% of 
cases rang (from 0 to 17%) . MDR-TB is present in five countries surveyed had 5% of TB patients with 
MDR-TB. In the Dominican Republic, 10% of TB patients had MDR-TB (WHO 1997). 
 
  10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  11
 
1.5.2.2 Distribution of tuberculosis in Sudan  
 
The best indicator of the extent of the tuberculosis problem in Sudan is the average annual risk of 
infection (ARI), which is the proportion of the population that is likely to be newly infected over a 
period of one year. The ARI is derived from studies of the prevalence of tuberculin positively. An ARI 
of 1%corresponds to an approximate incidence of 50 cases of pulmonary smear- positive tuberculosis 
per 100,000 populations. The incidence of all forms of tuberculosis 
 
is estimated at twice that rate. The prevalence of tuberculosis infection is probably very different in 
different regions of Sudan. The reported ARI of 1.8% represents an average that can 
  
be used at the central level for program planning and management (SNTP, 1994). The reported 
pulmonary tuberculosis cases by hospitals during 1987 and 1988 tuberculosis cases were 3749 and 
3983 respectively (SNTP, 1994) 
 
The estimated average incidence of all forms of tuberculosis is twice the incidence of pulmonary 
smear-positive cases, or 180 per 100,000. In the population of 24,400,000 in 1987 the total new cases 
was estimated to be 43,000. Estimating the population of reporting areas to be 15,000,000 (Khartoum, 
Central, Northern, Eastern, Kordofan region), and the number of cases of all forms of tuberculosis to be 
27,000, the coverage of case-finding is 67%. There are no official data on tuberculosis among displaced 
populations, but the average incidence can be considered to be close to that of settled population. In 
overcrowded camps it is likely that sputum-positive person will transmit the infection to more people 
than in the settled population. Malnutrition, stress and other problems may cause more breakdowns 
from infection to active disease among displaced populations than in the average Sudanese population. 
The only available data on displaced people were provided by the Sudan Council of Churches. Data on 
tuberculosis drug resistance patterns in the population and on the extend of the HIV epidemic among 
TB patients are not available in either displaced or settled populations (SNTP, 1994).  
 
1.2 Mycobacteriology 
1.2.1. Taxonomy of the genus Mycobacterium 
The genus Mycobacterium is the only genus in the family Mycobacteriaceae. The high G + C content 
of the DNA of Mycobacteria (62 to70 %) is similar to that of the other mycolic acid-producing 
bacteria, Nocardia (60-69 %) , Rhodococcus (59-69 %),Corynebacterium  suborder Corynebacterineae 
(Stackebrandt et al.,1997) Gordonia, Skermania and Tsukamurella (51-59 %), (Chun et al.,1996; 
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Goodfellow et al., 1998). This similarity may support the consolidation of these genera into a single 
family. (Wayne and Kubica 1986).  
A natural division occurs between slowly and relatively rapidly growing species of mycobacteria. Slow 
growers require more than 7 days producing easily seen colonies on solid media from a dilute inoculum 
under ideal culture conditions. Rapid growers require less than 7days under comparable conditions. In 
practice, different sets of biochemical tests are necessary to characterize slowly growing and rapidly 
growing species. (Wayne and Kubica, 1986). 
 
M. kansasii is the name currently given to photo-chromogenic (yellow bacillus) originally described in 
1953. Studies of the base sequences of the 16S r RNA and of catalase serology suggest that M. 
kansassii is phylogenetically very closely related to a non-pathogenic, slowly growing, non-pigmented 
species, M. gastri (Wayne and Diaz, 1982; Rogall et al., 1990).  
1.2.2. Description of the genus Mycobacterium 
The mycobacteria are slightly curved or straight bacilli, 0.2 to 0.6 by 1.0 to 10um in size, sometimes 
with   branching. Filamentous or mycelium-like growth may occur, but it easily fragments into rods or 
coccid elements.   Mycobacteria have cell walls with a high lipid contents that include waxes having 
characteristic mycolic acids  with long, branched chains (Wayne and Kubica, 1986). 
 The high lipid content of the cell wall excludes the usual aniline dyes. Mycobacteria are not readily 
stained by   the Gram methods but are considered Gram positive. Special staining procedures are used 
to promote the uptake   of dye, and once stained; mycobacteria are not easily decolorized even with 
acid-alcohol. This resistance to   decolourization partly or completely lost at some stage of growth by 
some proportion of the cells of some species.  Cells of rapidly growing mycobacteria may be less than 
10% acid fast. (Wayne and Kubica, 1986) 
The mycobacteria are aerobic, non-spore-forming, non-motile bacilli. Colony morphology varies 
among the  species. M. tuberculosis forms rough colonies with the bacilli compacted into curving 
strands (cords). In contrast,   MAC usually forms smooth transparent colonies with the bacilli arranged 
in no definite pattern on primary  cultures. M. kansasii is intermediate between the previous examples, 
forming slightly rough colonies. Diffusible  pigment is rare, but colonies of some species are regularly 
or variably yellow, orange, or rarely, pink. Some  species require light to form pigment 
(photochromogens), and others form pigment in either light or dark   (scotochromogens). Aerial 
filaments are rarely formed and are never visible without magnification. (Patrick, 1995). 
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Growth rates for mycobacteria are slow to very slow, with generation times varying species and 
ranging from 2 to 20 hrs. Easily visible colonies may be produced after two days to eight weeks of 
incubation under optimal  conditions, depending on the species. Optimal temperatures for growth vary 
widely among species, ranging from  30 to almost 45˚C, most species adapt readily to growth on 
simple substrates, using ammonia or amino acids as  nitrogen sources; and glycerol as a carbon source 
in the presence of mineral salts. Some species require medium  supplements such as hemin, 
mycobactins, or other irons transports compounds. M. leprae and M. intermedium  Which isolated from 
AIDS patients in Germany have not been cultured outside of living cells (Patrick,1995). 
A grouping system of Non-tubercle mycobacteria (NTM) based on pigmentation, colonial morphology 
and  growth rate was established by Runyon, (1959). It soon became apparent that all species of 
mycobacteria did not  fit within the four groups of the Runyon scheme. Clinical laboratories have 
abandoned the Runyon groups in   favour of identification to species level. The term atypical 
mycobacteria is of historical interest but should not be  used by clinical laboratories when referring to 
non- M. Tuberculosis mycobacteria. When this species were first   described, they were grouped 
together as atypical mycobacteria because they were not typical of M. tuberculosis.  Obviously, since 
these mycobacteria are not atypical but are characteristic of their own species, the term NTM is 
preferable when referring to these species as a group. Whenever possible, species names should be 
used (Patrick,  1995). 
1.2.3. Clinically significant mycobacteria:  
The genus Mycobacterium includes obligate parasites, saprophytes, and opportunistic pathogens. Most 
species   are free living in soil and water, but the major ecological niche for other such as M. 
tuberculosis complex and M . leprae is diseased tissue of human and other warm- blooded animals 
(Wayne  et al, 1992). 
Descriptions of the diseases associated with the clinically important and potential pathogenic species of 
 mycobacteria is shown in (table 1). (Lawrence et al, 1992). 
1.2.4 Biochemical methods of distinguishing between species of genus Mycobacterium  
Mycobacteria should always be identified to the species level if possible. According to the traditional 
methods, mycobacteria are usually identified by traits such as rate of growth, colonial morphology, 
pigmentation and biochemical test (table 2) (Patrick, 1995). And molecular methods were used to 
distinguish between species of genus Mycobacterium, such as Finger printing, and sequencing. M. 
tuberculosis complex includes the species M. bovis, M. microti and M. africanum. M. bovis was the 
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name given to the bovine tubercle bacillus in 1896. The bacillus of Calmette-Guerin (BCG), which is 
used as a vaccine against tuberculosis in many parts of the world, conforms to the properties described 
for M. bovis except that its pathogenicity is more attenuated, M. africanum discover by Castets 1969 
and its type strain is American Type Culture Collection (ATCC 25420) it is a group of strains causing 
human tuberculosis and taxonomically were assigned to two cluster; strains from  West Africa (similar 
in many respects to the human type) and strains from Rwanda and Burundi (closely resembled the 
bovine type).its mycolic acid pattern type α- keto- methoxy, (Goodfellow and Magee, 1998) M. microti 
also occupies a position along the phenotypic continuum between M. tuberculosis and M. bovis 
(Patrick, 1995) 
Mycobacterium avium Complex ( MAC) consists of 28 serotypes of two distinct species M. avium and 
M intracellular, and has in the past also included three additional serovars  of M. scrofulaceum  (M. 
avium ,M intracellulare and M. scrofulaceum complex ). Inclusion of M. scrofulaceum in the MAC is 
no longer appropriate, given recent advances in mycobacterial systematics (Wayne and Sramek, 1992). 
The criteria used to distinguish M .avium from M. intracellulare are now well established. There 
subspecies of M. avium were proposed on the basis of phenotypic characteristics and genetic studies: 
M. avium subspecies avium, M. avium subspecies paratuberculosis, and M. avium subspecies. 
silvaticum (Thorel, et al., 1990)  The International Working Group on Mycobacterial taxonomy has 
suggested that there is taxonomic evidence for a third species within the MAC (Wayne et al, 1991) 
1.2.4.1 Ziehl Neelsen microscopy for Acid-Fast Bacilli 
The "acid-fast" staining reaction of mycobacteria, a long with their beaded and slightly curved shape, is 
a valuable aid in the early detection of infection and in the monitoring of therapy (Cowan and Steel, 
1995). The finding of acid-fast bacilli in the sputum, is often considered presumptive evidence of active 
tuberculosis and sufficient causes to initiate therapy.  It has been estimated that there must be 10.000 
acid-fast bacilli per ml of sputum to be detected by microscopy. With continued drug treatment, more 
organisms are killed and fewer shed, so that following the number of stainable organisms in the sputum 
during treatment can provide an objective measure of response before the results of cultures is a viable 
from 3 to 6 weeks later (Hobby et al, 1973). Reports from examination of stained smears from clinical 
specimens should provide some quantitation of the number of acid-fast bacilli present and the degree of 
activity of the disease (David, 1976).  
1.2.4.2 Isolation of Mycobacterium tuberculosis 
Specimens from patients with tuberculosis usually contain mixed bacterial flora. Methods for the 
collection of specimens should be directed toward minimizing the number of contaminating bacteria 
(Krasnow et al, 1969). 
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 M. tuberculosis show faster growth with fewer contaminants when collected early in the morning. 
Although it has been noticed that 24-hours sputum collections will ultimately yield more positive 
cultures than early morning specimens (Krasnow et al, 1969), growth is usually slower and 
contamination rate is significantly higher with the sputum pools (Kestle, et al, 1967). Three early 
morning specimens will usually be sufficient to identify the patient with active disease (Krasnow et al, 
1969). 
Specimens submitted for recovery of mycobacteria were first treated with an alkaline or acid 
decontamination agent to reduce bacterial overgrowth and liquefy any mucus present to promote 
concentration of the organisms by centrifugation. After a carefully timed exposure of the specimen, 
while being mechanically shaken, the acid or alkaline solution was neutralized and then centrifuged at 
high speed to concentrate the mycobacteria. The centrifugal force should be as high as possible because 
the lipids content of the mycobacterial cell wall provides a buoyant effect and makes their specific 
gravity close to unity. For this reason the selective sedimentation of mycobacteria in a thick, viscous 
sputum specimen was difficult. Exposure of specimens to strong decontaminating agents such as 3 or 4 
percent NaoH, or 5 percent Oxalic acid, must be carefully timed to prevent excessive chemical injury. 
Neutralization of a strong decontaminating solution requires an equally strong acid or alkali, and often 
titration to a neutral end point might be incomplete with the specimen remaining either strongly 
alkaline or acid. Benzalkonium chloride should be inoculated to egg-base culture media in order to 
neutralize the growth inhibition characteristic of benzalkonium chloride. The concentrate should be 
neutralized by adding lecithin if it is to be inoculated to agar base media (Runyon et al, 1974). In 
response to the increased need to recover mycobacteria for susceptibility testing Kubica, et al.(1975) 
Contaminating bacteria, particularly gram-positive bacteria, are controlled in part by the addition to the 
medium of aniline dyes such as crystal violet and malachite green. The concentration of aniline dye in a 
medium is an important variable as light increases over the specified amount can result in significant 
inhibition of mycobacterial growth as well as growth of contaminants. Mycobacterial culture media 
contains anti-microbial agents to suppress bacterial and fungal contamination been used for many 
years. One of the more commonly used selective culture media was developed by Gruft, who added 
penicillin, nalidixic acid, and RNA to Löwenstein-Jenesen medium (Gruft,1971). A medium containing 
cyclohexamine, lincomycin, and nalidixic  
acid was also effective in the control of fungal and bacterial contaminants (Petran and Vera, 1971). 
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1.2.4.3 Molecular methods 
  
1.2.4.3.1 The Polymerase Chain Reaction (PCR) 
 
The polymerase chain reaction (PCR) is a rapid and powerful procedure for the in vitro generation of 
millions of copies of a specific deoxy ribonucleic acid (DNA) sigment. This  
technique first introduced in 1985 by Sacki et al., as the worldwide resurgence of tuberculosis has 
prompted the development of new (molecular) techniques to classify the bacillus, have advantages in 
help understanding the transmission of the disease.  
 
PCR is an in vitro nucleic acid amplification method. The reaction comprises repeated thermal cycling 
of the reaction mixture .the thermal cycling serves to dissociate the products of the previous thermal 
cycle then allow the association of these dissociated products with further reaction starting materials for 
another phase of synthesis .(Saiki, et al, 1985 and 1988) . Specifically, substrate DNA is denatured at a 
high temperature to give single-stranded (template) molecules. This is followed by short 
oligonucleotide primers (amplimers) annealing to specific, nucleotide-sequence-defined regions of the 
template at a lower temperature. The positions where the amplimers anneal to the template define the 
(target) the thermal cycle is concluded by the amplimers being enzymatically extended by the coupling 
of appropriately base-paired deoxynucleoside triphosphates (dNTPs) on the template at an intermediate 
temperature, thus producing another double-stranded DNA (ds DNA) copy of the original target.  
Each PCR cycle comprises a set of time and temperature-controlled incubation. The function of each 
incubation is to: 
First: Denature the target nucleic acid at temperature in the region of 94o C .  Second: Annealing 
amplimers at a temperature dependent on their calculated    annealing temperature (usually in the rage 
30-60oC) 
Third: Extend the primers by the thermostable DNA polymerase catalyzed addition of nucleotides to 
the 3’ end of each primer at a temperature of a bout 72oC. 
 If each PCR cycle were 100% efficient, each cycle would give rise to a doubling of the number of 
copies of the original target sequence, since the product of one PCR cycle becomes additional substrate 
for the next. The PCR process can therefore give rise to millions of copies of the target sequence, 
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enabling trace amounts to be detected against a background of a complex mixture of sequences. PCR 
may be used to analyze or determine the presence of specific DNA targets or, after a reverse 
transcription step. RNA sequences can also be amplified as DNA copies. (Saiki, et al., 1995 and 1988). 
1.2.4.3.2 Mutational analysis  
Several groups of investigators have developed Polymerase Chain Reaction (PCR) assays for direct 
detection and identification of M. tuberculosis in clinical specimens (Brisson et al., 1991; Eisenach et 
al., 1991; Kolk et al., 1992; Shawar et al., 1993). Also many PCR-based stratagies have been used to 
detect mutations in genes of interest which include DNA sequencing ( Musser et al.,1995 ) and 
Dideoxy fingerprinting (Felmlee et al., 1995), heteroduplex analysis (Williams et al., 1994 ). 
Restriction Enzyme Digest, (Wegenack et al., 1997) and Single Strand Conformation Polymorphism, 
(De Beenhouwer et al., 1995) 
 
1.2.4.3.2.1 Restriction fragment length polymorphism (RFLP) 
The main idea of this method is to amplify the target gene by the specific primer and cut the Wilde 
types of the gene with specific enzyme and the mutant type were not cut. (Victor et al., 1997 and 
Wegenack et al., 1997) 
 
1.2.4.3.2.2 Single Strand Conformation Polymorphism (SSCP) 
This method depends on the mobility shift of the mutant gene (Victor et al., 1997; Telenti et al. 1993) 
and the use of probes (De Beenhouwer et al., 1995; Rossau et al., 1997).  
 
1.3 Chemotherapy: 
1.3.1 Chemotherapy - the early days 
 As mankind has been affected by tuberculosis for at least 5,000 years, a plethora of treatments, ranging 
from traditional healing to surgery, has been described. It was not until 1943, however, when Selman 
Waksman discovered streptomycin that physicians had at their disposal a powerful tuberculocidal agent 
with scientifically proven activity. Shortly after wards, in 1946 para-amino-salicylic acid was shown by 
Jorgen Lehman to be active against M. tuberculosis and in 1952 three pharmaceutical companies 
simultaneously announced the discovery of the exquisitely potent anti-tuberculosis drug isoniazid. In 
the early days of tuberculosis chemotherapy, these compounds were used individually and in many 
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cases, despite making a good initial recovery, the patients relapsed with a drug -resistant form of the 
disease. It is easy to understand why, as frequency of mutation to streptomycin resistance is now 
known   to be-10-6 and it is not uncommon for patients with pulmonary disease to harbour such 
numbers of tubercle bacilli in a single lesion (Canetti, 1965) .consequently, regimens were developed 
in which streptomycin was associated with another drug, as it was correctly reasoned that the 
streptomycin resistant mutants present in the population would remain susceptible to the second drug 
(Medical research council,1962). 
This work culminated in the first generation of multi-drug treatment regimens for tuberculosis. These 
were subsequently improved and strengthened as newer more powerful and better tolerated drugs. Such 
as ethambutol and rifampicin were introduced in 1962 and 1967, respectively. Pyrazinamide, a 
compound that is bactericidal at acid pH and acts on intracellular bacteria, was also found to be of great 
value. No new anti-tuberculosis compounds have been developed by the broad spectrum 
fluoroquinolone, sparfloxacin, has been shown to be highly active against M .tuberculosis in 
experimentally infected mice (Lalande et al., 1993).  
1.3.2 Short course chemotherapy 
As a result of the research and many controlled clinical trials, the current standard regimen for 
chemotherapy was established (WHO, 1983). 
 The short course chemotherapy treatment lasts 8 months and consists of two phases. During  the initial 
intensive phase, which consists of 2 months, four drugs (isoniazid, rifampicin, pyrazinamide or 
ethambutol and streptomycin) are given daily; whereas, during the continuation phase, lasting 6 
months, isoniazid and rifampicin are administered at best daily and at worst twice weekly. When 
pyrazinamide is not employed during the intensive phase, the treatment duration is increase to 9 months 
(WHO, 1997; American thoracic society, 1986). Numerous studies have shown that success rate for the 
treatment of drug sensitive tuberculosis by short course chemotherapy was close to 100 % provided 
that the regimen was adhered to rigorously both by the patient and the clinician (Grosset, 1989, and 
Iseman, 1993)  
Although it is strongly recommended that short course chemotherapy be employed for treating 
tuberculosis, this is not always possible. In many developing countries, some of the more expensive 
bactericidal drugs, such as rifampicin, are not available. This often results in their replacement by 
second-line drugs, such as thiacetazone. In much of Africa, it is not uncommon to treat patients for 12 
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months with a regimen including isoniazid and thiacetazone, supplemented with streptomycin in the 
initial 2 months (Cole and Telenti, 1995)  
 
1.4 Drug resistance: 
Drug resistance is defined as a decrease in the vitro susceptibility of M. tuberculosis of sufficient 
degree to be reasonably certain that the strain concerned is different from a wild strain that has never 
come into contact with the drug. 
Primary resistance refers to the resistance observed following infection with an isolate of M. 
tuberculosis that is already resistant to a given anti-tuberculous agent; whereas, secondary, or acquired 
resistance corresponds to drug resistance, which emerges during treatment (Bradford et al., 1996). The 
latter is generally the result of poor compliance on the part of the patient, or poor conception of the 
regimen and inadequate supervision on the part of the physician (Iseman, 1993; Vareldzis et al., 1994). 
Primary drug resistance in industrialized countries has been periodically survey since the introduction 
of short course chemotherapy, and generally found to be at a low level (Canetti, et al, 1972). 
1.4.1Origin of drug resistance 
Drug resistance can emerge to all of the antibacterial drugs used in the treatment of mycobacterial 
disease. It occurs most commonly when a single drug is given alone and when the viable bacterial 
population in the lesion is large. In tuberculosis, it first appears after an interval of at least two weeks 
and more usually one to four months after the start of chemotherapy (David III, 1970). 
The occurrence of drug resistance is widely thought to be due to the overgrowth of sensitive organisms 
by mutant resistant bacilli present in wild strains before they were ever in contact with drug concerned 
(Canetti,1961) performance of the fluctuation test of Luria and Delbruck indicated mutation rates in 
Mycobacterium tuberculosis of about 2X10-8 for resistance to isoniazid and streptomycin, 2X10-10 for 
rifampicin and 1X10-7 for ethambutol (David iii, 1970).The proportion of resistant mutants is variable 
from one culture to another and for most drugs, is much greater for mutants with low minimal 
inhibitory concentration (MICs) that for those with higher (MICs) (Cantetti and Grossel,1961; 
Mitchison,1961) 
In every approximate term, the ratio of mutants able to grow during treatment to sensitive organism in 
wild strains is about 1:106 for isoniazid and Streptomycin and 1:107 for rifampcin (David, 1970; 
Canetti, 1961). 
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Mutation to drug resistance is usually though to occur in bacterial chromosomes. The isolation of 
plasmids from opportunist or saprophytic mycobactria has been described (Crawfordeta, 1979. 
Mlzuguchi et al, 1981 -Jones et al, 1972). Though not from Mycobacterium tuberculosis, 
Mycobacterium bovis and Mycobacterium leprae). Although it has been claimed that these plasmid, 
associated with aminoglycoside resistance. The issue is still uncertain, it seems reasonable to assume 
that resistance to isoniazid rifamipcin, pyrazinamide, dapsone and other non-aminoglycosides in 
tubercle bacilli is probably chromosomal. In the treatment of tuberculosis, the pattern of the emergence 
of resistance suggests little linkage between unrelated drugs, even among the aminoglycosides, though 
there are several well established patterns of cross resistance between closely related drugs (Mitchison 
et al, 1984). The species of Mycobacteria that are well adapted to parasitic role in man, Mycobacterium 
tuberculosis Mycobacterium africanum and Mycobacterium bovis all exist within closed lesions in 
human or animal hosts and do not come into contact with other bacteria, including other strains of 
mycobacteria, which might transmit plasmid-mediated resistance system could not readily be exploited 
by them to increase their genetic variability. 
1.4.2 Mutation structure and response to chemotherapy 
The relationship between mutant structure, drug dosage and the response of newly diagnosed patients 
with pulmonary tuberculosis to treatment with isoniazid was thoroughly explored during the period 
when this drug was being used alone in clinical studies (WHO, 1960 and 1963; Mitchison, 1973). The 
rate at which Isoniazid is a acetylated to microbiologically inactive acetyl isoniazid in man is 
genetically controlled by a single gene, about 40 % of most populations (including Indians) being 
virtually indistinguishable homozygous or heterozygous rapid in activators and the remainder slow in 
activators. In a comparison of the plasma Isoniazid concentration time curves for rapid and slow in 
activators, rapid in activators had only a slightly lower peak concentration than slow in activators, but 
had much smaller areas under the curve (exposure) and much shorter duration of coverage during 
which bacteriostatic concentration is maintained according to the mechanism suggested to explain the 
association, Isoniazid resistant mutants with the increasingly high degree of resistance were inhibited 
by the concentrations reached near the peak as the size of the dose of Isoniazid was raised (Selkon et 
al., 1964) It is of interest that the improvement in response with increasing dose size appeared to flatten 
off at about 8.7 mg/kg b/w. in slow in activators, when the peak concentration was about 6mg/l.(Canetti 
G et al;1961) found that mutants capable of growth on 5mg/l or more in vitro were all highly resistant, 
so that one would expect no increase in the number of mutants inhibited in the lesion when patients 
were treated with doses higher than about 8.7 mg/kg.   
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1.4.3 Nomenclature 
A specialized nomenclature is used to describe the isolation of resistant organisms from patients in 
relation to their history of previous chemotherapy (Mitchison, et al, 1984). 
Primary resistance is the term used when the strains are either naturally resistant to the drug 
(Mycobacterium bovis resistance to pyrazinamide) or have acquired resistance from another person 
resulted to in effective chemotherapy .Initial resistance is the isolation of resistant strains from patient 
who claims never to have had chemotherapy ,it includes primary and undisclosed acquired resistance 
which is due to insufficient patient who never trust between him and his new medical advisers ,patients 
may be give a frank history of previous successful chemotherapy and then said to have disclosed 
acquired resistance (Mitchison, et al 1984). 
 
1.4.4 Factors influencing the emergence of resistance  
The theory, giving two drugs together should eliminate the emergence of resistance organisms since 
one drug should prevent the growth of mutants resistant to the other drug. As mutants comprise about 
1:106 of the bacterial population in tuberculosis, adoubly resistant mutant should only occur once if the 
total population were about 1012,prehaps 100 times higher than the occurrence rate even in the 
extensive pulmonary tuberculosis.(Mutchision,1984) . 
 
1.4.4.1 Cross resistance 
There may be cross-resistance between the two drugs, so that inhibition of one or both sets of mutants 
is absent or incomplete, for examples in M. tuberculosis are partial cross resistance between 
thiacetazone and ethionamide (Bartman et al 1960) and capreomycin, viomycin and kanamycin 
(Tsukamura et al, 1975; Clatchy et al, 1977) while complete cross resistance occurs between 
kanamycin and amikacin (Allen et al, 1983). In practice, cross-resistance is a rare cause emergence of 
resistance (Mutchision, 1984). 
 
1.4.4.2 Initial resistance 
Patients may be started on treatment with two drugs, but have initial resistance to one of them, so that 
there is little or no inhibition of the mutants resistant to the other drug. However it should be noted that 
10 of 20 patients with severe pulmonary tuberculosis and primary isoniazid resistance showed a 
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definite initial bacteriological response to treatment with isoniazid alone or isoniazid and para-amino 
salicylic acid (PAS), (Devadattas et al, 1961) and four out of ten patients with strains initially 
resistance to para-amino salicylic acid. Streptomycin and isoniazid nevertheless attained quiescent 
disease when treated with these three drugs (British Medical Research Council, 1972). 
1.4.4.3. Drug potency 
Drugs vary in their ability to suppress the emergence of resistance to another drug. A highly potent 
drug is able to prevent the growth of -and usually kills- all the organisms in the lesion and continue to 
do so despite minor irregularity in drug taking by the patient. This implies that drug concentrations 
considerably higher than drug (MIC) are present for some of the time that drug action is not reduced by 
pH or environmental factors, and that exposure to the drug is followed by a period of several days (in 
tuberculosis), in which the organisms do not began to grow again (Dickinson, et al,1973). Example of 
less potent drugs are ;streptomycin because it dose not act on bacilli in an acid environmental many 
occur inside macro phases or extra cellular in areas of acute inflammation. Pyrazinamide because it 
only acts on bacilli at pH values of less than 5.6, thiacetazone because it's only bacteriostatic and bacilli 
will start to grow again if a dose is missed .Other drugs such as ethambutol, kanamycin and 
ethionamide can only be given in sub-optimal dosages because of the risk of toxicity (Mitchison et al, 
1984)  
 
1.4.4.4 Number of viable bacilli  
 The probability of resistance emerging is clearly greatly influenced by the number of viable bacilli in 
the lesions at the time that chemotherapy is started or a regimen changed. In tuberculosis, the risk is 
greatest in cavitated, pulmonary lesions with bacillary populations of perhaps 108-109 colony forming 
units (c.f.u.) which are usually treated with three drugs initially (East and Central African and British 
Medical Research Council, 1983). However, the risk is so small in closed tuberculomata; with 
populations usually of less than 100c.f.u. that monotherapy is justified. Lesions with fairly small 
bacterial populations, such as bone and joint tuberculosis and tuberculosis meningitis, could probably 
be safely treated with a two-drug regimen of isoniazid and rifampicin, since even if there was initial 
resistance to isoniazid, the probability of there being sufficient organisms to allow rifampicin resistance 
to emerge would be small. Again, monotherapy with isonaizid or, an experimental basis, with 
rifampcin is to be recommended for chemoprophylaxis in contact or patient with minimal inactive 
lesion. While chemotherapy for pulmonary lesions is usually started with two or three drugs given 
together for the first 2-3 months continuation can safely be with isoniazid alone because the number of 
  27
viable bacilli at risk from which mutants might grow has by then been reduced to a very low level. 
(East and Central Africa and British Medical Research, 1983) 
 
1.4.5 Prognostic importance of resistance 
Data on the prognostic influence of initial drug resistance in tuberculosis have been draw entirely from 
studies carried out under the auspices of the Medical Research Council, since it is only in these studies 
that treatment was continued without alteration despite a finding of initial resistance, and the methods 
of sensitivity test were also the same.  
The influence of primary or initial resistance, and on the results of the chemotherapy of newly 
diagnosed, severe, pulmonary tuberculosis with isoniazid alone or with another weak second drug such 
as PAS or thiacetazone (the prognostic effect was considerable. Thus, in the pooled result of four 
controlled clinical trials carried out at the Tuberculosis Chemotherapy Centre, Madras). 
15 (71%) out of 21 patients with primary isoniazid resistance had an unfavourable response with 
bacteriologically active disease at the end of treatment, as compared with only 14 % of patients with 
sensitive organisms on admission to the study .Similar results were obtained in four co-operative 
studies in East African centres in which patients were treated either with isoniazid and PAS or with 
isoniazid and thiacetazone, these results were obtained in the 1960s when there was little alternative to 
PAS or thiacetazoneas companion drugs to be given to prevent the emergence of resistance drugs to 
isoniazid, particularly in developing countries.  
The position has, however, completely changed as the result of introduction of newer and more potent 
drugs and the development during the last decade of short course regimens which greatly reduce the 
period of treatment necessary to obtain a bacteriologically quiescent status (Fox, 1981). The most 
important of these drugs, whose action has been reviewed elsewhere, (Mitchison, 1979) is rifampicin 
excellent both as a sterilizing drug which kills the last few semi dormant organisms in the lesion and 
also, as we have seen, in preventing growth of organisms throughout the lesion and therefore the 
emergence of resistance to a companion drug. 
 Pyrazinamide is almost as good as a sterizing drug ,but is much less effective than rifampicin in 
preventing the emergence of resistance Ethambutol appears to be of no value as a sterilizing drug, but 
is moderately effective in preventing resistance.  
The prognostic influence of initial resistance to isoniazid alone or isoniazid and streptomycin in the 
pooled results from a series of studies of short course regiment including these drugs,(Mitchison, 1982) 
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The results obtained in patients with initially sensitive organisms are not included since they are, with 
very few exceptions, uniformly favourable, irrespective of the regimen .Results in patients with initial 
resistance to streptomycin only are also omitted, since this resistance did not appear to influence the 
response to treatment. (Mitchison, 1984).   
1.4.6 Molecular basis for drug resistance 
M. tuberculosis is naturally resistant to many antibiotics, particularly those belonging to the β – lactam, 
macrolide or tetracycline families, and this may be a result of its highly lipophilic cell envelope acting 
as an efficient permeability barrier (Cole and Telenti, 1995). There are many mycobacterial genes with 
mutations associated with anti-tuberculosis resistance (table 3).  
1.4.6.1 Streptomycin  
Streptomycin was first shown to be an effective antitubercular drug in 1944 (Schatz and Waksman, 
1944). The liquid MIC (Minimum Inhibitory Concentration) of streptomycin against M. tuberculosis 
has been reported to be 0.4-1.5 ug/ml (Heifets, 1994) making it one of the most effective early 
antitubercular drugs. The antibacterial activities of streptomycin, and related aminoglycosides, are due 
to the inhibition of prokaryotic protein translation. Specifically, initiation of mRNA translation appears 
to be inhibited, althogh translational accuracy is also affected (Benveniste and Davies, 1973). Mutation 
associated with streptomycin ( STR) resistance in M. tuberculosis  have been identified in two targets, 
the 16S rRNA gene (rrs) and the gene (rpsl) encoding ribosomal protein S12 (Finken et al., 1993 and 
Nair et al., 1993). Acommon mechanism of resistance to aminoglycosides antibiotics in other bacteria 
is drug inactivation via acetylation (Benveniste and Davies, 1973). However, this mechanism of 
resistance has not been reported in M. tuberculosis. In stead two classes of mutations account for some 
80% of the high level streptomycin resistance in M. tuberculosis (Honore and Cole, 1994). The first 
consists of point mutations in the ribosomal S12 protein(Douglass et al., 1993 and Yamada et al., 
1985) encoded by the rpsl gene, resulting in Single amino acid replacements (Finken et al., 1993 and 
Nair et al, 1993). These mutants account for two thirds of the resistant mutations. Mapping of these 
mutations revealed that all mutations occurred in highly conserved region of the gene encoding one of 
two critical lysine residues (K43 and K88). In all cases, either K88 was converted to an arginine 
residue or K43 was converted to either an arginine or threonine residue (Meier et al, 1994).  
1.4.6.2 Rifampicin 
Rifampicin a semi-synthetic derivative of the natural product rifampicin, obtained from culture 
filterates of Streptomyces mediterranei, was introduced in 1972 as an anti tubercular drug (Woodley et 
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al, 1972). Rifampicin is extremely effective against M. tuberculosis (MIC. 1-0.2 ug/ml) and its rapid 
bactericidal activity (Mitchison. 1985) helped to shorten the course of treatment against drug- 
susceptible infections. For more than 20 years the target of rifampicin action in M. tuberculosis has 
been assumed to be the mycobacterial RNA polymerase (Siddiqi et al. 1981).  
Resistance to rifampicin in many E. coli strains was known to arise as a result of missense and other 
mutations occurring in a discrete region of the rpoB gene (Jin and Grosst, 1989; Ovchinnikov, et al., 
1981and 1983).                 
Resistance to rifampicin is incresing rapidly as a result of its widespread use. Rifampicin-resistant 
tuberculosis, often observed in conjunction with isoniazid resistance, leads to a longer- treatment 
period and significantly poorer chemo-theraputic outcomes. Resistance has been observed in 3.9% of 
all cases nationally, but in 9.0% of patients who have been previously treated for tuberculosis (Bloch, 
et al., 1994). Resistance is acquired at a rate of 18-8 in cultures of M. tuberculosis, evidence of a 
single- step mutational event (Tsukamura, 1972). The genes encoding the ß subunit of the 
mycobacterial RNA polymerase, rpoB, have been sequenced from M. tuberculosis (Miller et al., 1994). 
The vast majority of rifampicin resistance- conferring mutations in the mycoacterial rpoB encoded 
RNA polymerase are single nucleotide changes that result in single amino acid substitutions (93%) 
(Honore and Cole, 1993). The remaining mutations are insertions (3%) and deletions (4%), but all 
mutations map to the presumed rifampicin binding site between amino acid positions 511 and 533. In 
two recent studies, the most commonly encountered amino acid substitutions occurred at Histadine526 
and Serinine531 (60% of all mutations (Williams, et al, 1994) and additional mutations   have been 
mapped to positions 512, 513 and 516 (20%) (Donnabella et al, 1994). A very small percentage of 
rifampicin resistant clinical M.tuberculosis isolates do not map to the 511-533 region of RNA 
polymerase, but may be preset in the carboxy terminal region of the protein (Blanchard, 1996). 
 Other species of the genus Mycobacterium where found to have the same mutations in the same gene 
but in different locations, as M. leprae (Honore, et al, 1993; Guerrero, et al, 1994.) , M. avium 
(Williams, et al, 1994) and M. africanum (Williams, et al, 1994;.Vareldzis,et al, 1994) 
 
  1.4.6.3 Isoniazid (INH) 
Primary resistance of M. tuberculosis to isoniazid ( INH) arises in the laboratory at an estimated 
frequency of 10-5 to 10-7 (David, et al, 1971), which is several orders of magnitude greater than that 
reported for RIF (Zhang ,et al, 1993). In an effort to elucidate the molecular mechanism responsible for 
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the observed decreased catalase activity associated with INH-resistant organisms, (Zhang, et al, 1992). 
Cloned and Heym et al. (Heym, et al, 1993) characterized the gene (KatG) coding for the M.  
tuberculosis catalase – peroxidase. The M. tuberculosis enzyme is an 80000-Da protein with substantial 
homology to hydroperoxidase I from E.Coli, catalase-peroxidase from M. intracellulare (Morris, et al, 
1992), and other bacterial catalase – peroxidases. Transformation of M. segmatis and M. tuberculosis 
with wild-type katG restored INH susceptibility to resistant isolates (Zhang, et al, 1993) a result 
confirming that the protein product of katG (katG) participated in INH action. In addition, it was 
observed that in two of three high-level (MIC >50µg/ml )resistant patient isolates katG was deleted 
from the chromosome ((Zhang ,et al, 1992). These investigators concluded that resistance in a subset of 
M. tuberculosis strains is due to loss of the complete katG gene . However, they also observed by 
Southern analysis that most INH-resistant strains had an apparently intact katG gene, although the 
levels of catalase-peroxidase activity recorded for these organisms were greatly decreased. In addition. 
Stoeckle, et al . (Stoeckle, et al, 1993) studied by PCR 80 randomly selected isolates recovered from 
patients in New York City and found that 35 (90%) of 39 INH-susceptible and 31 (76%) of 41 INH – 
resistant strains contained apparently intact katG   sequences and therefore did not have a gross deletion 
of this gene . Moreover, there was no simple relationship between absence of katG and occurrence of 
high – level (>1µg/ml) INH resistance. These observations suggested that for most strains either simple 
base-pair (bp) changes resulting in (for example) missense or stop mutations or small deletions were 
associated with resistance. 
The observation that most INH-resistant M. tuberculosis strain did not have gross katG deletion 
suggested the need to more precisely analyze the structure of katG present in resistant organism. 
Several groups have now reported that many INH-resistant strains contain missense and other types of 
mutations organisms. For example, Altamirano et al (1994) studied nine INH – resistant isolates and 
one INH – susceptible patient isolate and found that a 237 bp fragment of katG could be amplified from 
eight of nine INH-resistant isolates. These eight INH –resistant organisms had missense mutations, 
deletions of 1 base, or insertions of up to 3 bases in the region studied (nucleotides 3 through 239 
located at the 5 end of the gene). 
Heym et al (1994) recently reported the results of characterization of the katG gene in 20 INH- resistant 
organisms and 16 strains that were resistant to both INH and ethionamide (ETH). For these organisms, 
the MICs of INH ranged from 0.2 to >10 µg/ml. These investigators found that 23 of 36 (64%) 
organisms had mutations in katG, as defined by SSCP analysis.  
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Characterization of katG sequences in 18 INH –resistant organisms with altered SSCP patterns found 
several types of mutation located predominantly in the region encoding the amino-terminal one-half of 
the protein (Heym ,et al, 1995) The most common mutation (n=7 strains) was a CGG?CTG change 
resulting in an Arg? Leu substitution at amino acid position 463. Four additional missense mutations 
were identified ,including GTG? GCG (f-met?Ala, position 1)in one strain ,GAC?GCC (Thr-275 
pro) in one strain, AGC?ACC (Ser-313 Thr) in five strains, and CTG?ATG (Leu-587Met) in one 
strain. Tow strains that had a deletion of 12 bp resulting in absence of amino acids 120 to 123 were 
identified, and one strain had an insertion of 3 bp (CAT, Ile) between codons 125 and 126. 
The availability of the crystal structures for related enzymes, including yeast cytochrome c peroxidase 
(Finzel et al, 1984), permitted several inferences to be made about structure-function activities of the 
katG product. The deletion reduce residues 120-123 and the insertion of Ile between amino-acids 125 
and 126 were predicted to result in diminution of catalase  activity, and it was shown that organisms 
bearing these mutations had only approximately 10% residual catalase-specify activity related to strains 
with wild-type katG alleles. The amino-acid replacements at position 275 ( Thr?Pro) and 315 
(Ser?Thr) were also predicted to result in decreased catalase activity because amino-acid residues 
located close to the equivalent positions in yeast cytochrome C peroxidase and E.coli hydroperoxidase 
are functionally important (Loemen et al, 1990; Pelletier et al, 1992; Sivaraja et al,1989) theses 
predictions were born out by enzymatic studies demonstrated M. tuberculosis strains with the position 
275 or 315 substitutions have virtually no detected catalase activity (Heym et al, 1994). In contrast to 
the diminished catalase activity observed among organisms with the mutations described above, strains 
with the Arg-463? Leu substitution had essentially wild-type levels of enzymes activity. 
KatG gene characterized also by Cockerill et al (Cockerill ,et al, 1995) in 15 strains of M. Tuberculosis 
For which INH MICs ranged from < 0.12 to > 32 µg/ml, including 9 resistant and susceptible strains. 
Sequencing of katG from all organisms 6 of 9 INH-resistant strains had one or more missense-
mutations, one strain had a non-sense mutation, one had an 8-bp deletion, and one had no mutations in 
the coding sequence. In Striking contrast to the data presented by Heym et al(Heym ,et al,1994), in 
which virtually all strains had  single amino-acid substitutions, 9 of the strains had  multiple missense-
mutations, including one organisms . Five of six INH – resistant strain with missense mutation had, in 
addition to other change, a G ? T transversion in codon 463, resulting in the substitution of Leu for 
Arg. The six INH- susceptible strains had none to 11 amino acid substitutions compared with a 
consensus sequence formulated from the data available for all 15 organisms; however, nine of the 
mutations affected Arg-463. The G? T change in codon 463 results in loss of a restriction enzyme site 
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recognized by Ncil and MspI and thereby generates a convenient strategy to rapidly screen large 
collections of organisms for this polymorphism. Analysis of 32 INH-susceptible and 43 INH-resistant 
strains demonstrated that 19 of 43 (44%) of resistant strains, but only 1 of 32 (3%) of INH-susceptible 
strains, had lost this restriction site and were presumed to contain the G?T mutation resulting in an 
Arg ? Leu substitution. 
 Moreover, sequence analysis of a region of katG encoding residues Ser-315 and Arg-463, and the inhA 
locus, in 10 susceptible and 51 INH-resistant bacteria had mutations in katG or the inhA locus. 
Interestingly, all 16 strains of M. bovis and M. microti had Leu-463 rather than Arg-463 is the ancestral 
condition in M. tuberculosis. Taken together , the data are consistent with results showing that very 
little katG allelic variation occurs in INH-susceptible strains, and a restricted subset of missense 
changes are repeatedly associated with INH resistance. Although there is evidence to suggest that one 
or more of the variant katG alleles confers INH resistance, there is clearly a need for additional 
molecular genetic data addressing the exact role of some of the non-synonymous substitutions 
described by several investigators. 
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     Table 3. Mycobacterial genes with mutations associated with anti-microbial resistance *  
Anti-
microbial        
agent 
Species Gene Size(bp) Product 
 
Rifampicin 
M. tuberculosis 
M. africanum 
 M. leprae 
M. avium 
 
rpoB 
 
157 
 
β-  sub-unit of RNA 
polymerase 
 
Isoniazid 
 
M. tuberculosis 
katG 
inhA 
kas A 
2,205 
810 
 
Catalase-peroxidase 
Streptomycin M.tuberculosis rrs 1,464 16S r  RNA 
reptomycin tuberculosis 
 smegmatis 
rpsL 272 Ribosomal protein S12 
* Adapted from Muser (1995) 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
 
 
 
2.1 Area and period of investigation 
      Two hospitals were selected for the collected of samples, namely: El Shaab Teaching Hospital at 
Khartoum and Hamed EL-Neel hospital at Omdurman, the hospitals were chosen because of the high 
number of  tuberculosis patients attending these centres. The collection was undertaken in the period 
between July  1999 to May 2000.  
      2.2 The clinical specimens  
2.2.1 Patients  
250 sputum specimens were collected from new tuberculosis cases before they were given anti - 
tubercle drugs.  The disease was suspected according to the characteristic TB symptoms         notably 
fever, productive sputum and weight loss (WHO, 1996). The patient samples were   selected randomly 
and were of different age groups and of both sexes, some of them were BCG vaccinated and others 
were not.  They came from different states of Sudan and represent different tripes. 
  
2.2.2 Samples collection 
Sputum specimens from the first productive deep cough of the morning were obtained from each 
patient in a sterile screw top plastic disposable cup container (Vderman International). Care was taken 
to avoid contamination of saliva or nasal secretions. Before sampling, patient was asked to rinse his 
mouth with water. 
 
2.3 Microscopy and culture methods 
 
2.3.1 Ziehl Neelsen stain procedure (ZN) 
Slides for staining were placed on a staining slide-rack over the sink with smeared side uppermost, 
their edges separated about one cm.  Thin smear from each sample was made, fixed with heat then 
stained with ZN method as fellows: a strongly acting dye with a mordant, was needed, carbol fuchsin, 
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was poured on slide with the application of heat to facilitate impregnation; this was followed by the 
decolourization with 20% sulphuric acid and 95% alcohol separately or 3% hydrochloric acid in 95% 
alcohol and then counter stained with methylene blue. Acid fast bacteria appear red in a blue 
background (Gowan and Steel, 1995).   
2.3.2Culture of M. tuberculosis  
Sputum sample was transferred to sterile, graduated, 50 ml plastic conical centrifuge tube, an equal 
volume of 4%NaOH solution was added, and the tube capped and then the contents mixed for 
approximately 20s on a vortex mixer until they were liquefied. The mixture was swirled by shaker for 
20 min to further mix the contents, then the solution was centrifuged for 20 min at > 3000xg. The 
supernatant was carefully decanted into splash-proof discard container containing phenol disinfectant.  
The sediment was washed by sterile distil water, and the supernatant was carefully decanted into 
splash-proof discard container containing phenol disinfectant. Sterile pipette was used for each tube, a 
few amount of sediment was took using separate sterile pipette for each tube, The sputum sediment was 
divided into two aliquots: the first part was used to prepare the smear for microscopic examination and 
from the second part 2-3 drops were inoculated on the surface of two solid culture media (Löwenstein-
Jensen medium). The specimen was incubated at 370C for at least 8 weeks.                                                        
2.4 Molecular detection of drug resistance 
There are many molecular methods to detect drug resistance; two of them were used to detect 
rifampicin (SSCP) and streptomycin (RFLP) resistant. 
2.4.1 Precautions to prevent contamination of molecular methods 
Prevention of contamination was accomplished by physical separation of different steps in the PCR 
procedure, using different pipettes, and wearing separated coats and gloves in each laboratory. The 
PCR mix was prepared in the PCR room, where work was conducted in a safety cabinet to prevent 
contamination to the PCR reagents. Chemicals used in the PCR and for the treatment of clinical 
samples were weighed in this room on a balance, which was used only for this purpose. Ultra-pure 
water was used to make the solutions, which were supplied kindly by Dr. M.E. Hamid, Faculty of 
Veterinary Medicine.  In the Pre-PCR room, clinical samples were treated in a safety cabinet and added 
to the PCR mix. Chemical decontamination of surfaces and equipment was done weekly in both rooms 
with sodium hypochlorite (Prince and Andrus, 1992).  The detection of PCR products by agarose gel 
electrophoresis was done in a third room (Post-PCR room).  
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 2.4.2 DNA extraction              
Approximately five colonies of M. tuberculosis were scraped from the L J slant and transferred to 1.5 
micro-centrifuge tube containing 100 µL of sterile distilled water. The preparation was vortex for 3-5 
min then heated  in a heating block at 80 oC for 30 min to kill M. tuberculosis and to release the DNA . 
Five microlitres were used for each PCR reaction.  
2.4.3 Molecular identification of acid fast isolates 
Tow molecular methods were used to identify of acid fast isolates; PCR and RFLP- fingerprinting 
2.4.3.1 DNA amplification of M. tuberculosis mutant genes  
PCR was performed in a total volume of 100µl reaction mixture containing 10X PCR buffer (10µl) , 25 
mM magnesium chloride (6µl), 10 mM dNTPs mixture (8µl),  each set of primers (2µl), 5 U/µl of 
Thermus aquaticus DNA polymerase (0.3µl) (supplied by Promega). The reaction mixture was overlaid 
with 1-2 drops mineral oil to avoid evaporation. The tubes were then subjected to 37 thermal cycles in 
a programmable thermocycler (Biometra) as follows: DNA was denatured at 94 °C for 3 minutes for 
one cycle followed by 94 °C for one min as secondary denatured and annealed at rang 50- 64 °C (The 
annealing temperature depend on the specific primer set – Tm = 4 (G+C) + 2 (A+T) (table 4) followed 
by extension at72°C for one min for 35 cycles and a final extension at 72 °C for 10 minutes for one 
cycle. 
2.4.3.2 RFLP – Fingerprinting 
RFLP – Fingerprinting, using Van Soolingen method was done to identify M. tuberculosis complex by 
using IS6110 and Mob II restriction enzyme as follow; 
2.4.3.2.1 Isolation of Genomic DNA from mycobacteria 
Several loops of colonies were transferred into a microcentrifuge tube containing 400 ul 1X TE, and 
were heated at 80 oC for 20-60 min to kill the cells.50 ul of 10 mg /ml lysozyme were added and the 
samples were well vortexed and spined down, then incubated for an hour at 37 oC .75 ul of 10% SDS 
(10gm / 100ml ddH2O) /proteinaseK (10mg / 1ml ddH2O) were added, shortly vortexed and incubated 
at 65 oC for 10 min.100ul of 5M NaCl (29.2 gm / 100ml dH2O ) and another 100ul of CTAB / NaCl 
solution (4.1 gm NaCl / log CTAB up to 100ml dH2O ) which was pre-warmed at 65 oC , were added, 
and the mixture was vortexed until the liquid has become milky solution, then incubated at 65 oC for 10 
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min. 750 ul of chloroform / isoamly alcohol (24 / 1 volume) were added, vrtexed for at least 10 sec, and 
centrifuged at room temp. for 5 min at 12,000g. 
All of the aqueous supernatant was transferred into a fresh microcentrifuge tube (180 ul),and carefully 
0.6 volume (450ul ) isopropanol were added to precipitate the nucleic acids, and the tubes were 
inverted up side down several times by hand. The amount of 1X TE in which the DNA should be 
dissolved, was estimated according to the size of the precipitate and was found to be 20ul. The samples 
were placed at -20 oC for 30 min, then spined for 15 min at room temp. in a microcentrifuge at 12,000g. 
Most of the supernatant was taken out, and 1ml of 70% ethanol was added and the tube was turned 
slowly up side down a few times, and spined for 5 min at 4 oC in a microcentrifuge, and the supernatant 
was discarded as much as possible. The tube was spined 1 min in a microcentrifuge and the last 
leftover of supernatant was cautiously discarded to make sure that all traces of ethanolwere removed. 
The pellet was permitted to dry at room temp for 10 min, and re-dissolved in 1X TE, using 25ul TE. 
Spectrophotometer was used to estimate the concentration of DNA of each sample. 
2.4.3.2.2 Digestion of chromosomal DNA by Pvu II 
About 4.5 ug of genomic DNA samples were digested in a final volume of 20ul in a microcentrifuge 
tube, and at the same time 4.5 ug of the reference strain H37Rv were digested. The volume of enzyme 
was less than 10% of the total reaction volume. 
9 ul DNA ( 4.5 ug ) 
2 ul 10X digestion buffer 
1 ul PvuII (10U / ul ) 
8 ul ddH2O  
 20 ul ( Total volume ) 
The sample was mixed and briefly centrifuged for 5 sec at 12,000g, then incubated for 1 hour at 37 oC. 
 
 
2.4.3.2.3.Confirmation of DNA concentration and enzyme digestion 
0.8% agrose gel in 1X TBE buffer was made for a small gel, and was swirled and cooled down to 65 
oC. The gel was poured in a tray without making air bubbles in the gel, and was left to solidify. The 
buffer vessel was filled with the 1X TBE. 5 ul of 5X DNA sample buffer with RNase was added to 20 
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ul of the DNA samples, then mixed and spined down for 5 sec. 5 ul of the lambda-Hind III mix were 
loaded in the first slot. Each DNA samples was loaded and electrophoresised for 20 min at 100V. A gel 
was stained in a EtBr solution for 5 min and destained in water for 20 min, and then viewed on an UV 
transilluminator using short waves. A picture of the gel was taken. 
2.4.3.2.4 Separation of DNA fragments by electrophoresis for southern blotting 
A large (16X24 Cm ) 0.8% agrose gel in1X TBE buffer was made. An EtBr was added to the dissolved 
agrose to a final concentration of 0.5 ug / ml, and was pouredin the gel-former and left to solidify. The 
buffer vessel was filled with the 1X TBE containing 0.5 ug / ml EtBr, and the gel was covered to a 
depth of about 2 mm. 5 ul of the lambda-HindIII was loaded in the first slot. Also  equal amounts of the 
genomic DNA samples were loaded in all slots. The samples were elctrophoresised for 10 min at 100V 
and the voltage was decreased to 30V and run overnight. The gel was checked on an UV 
transilluminator and electrophoresised further until the 2 kb lambda-Hind III band has reached a 
distance of 7 Cm from the wells.      
2.4.3.2.5 Blotting by the capillary method 
Agel–holder was placed up side down in a big tray and covered with a piece of Whatman paper that 
was wider than the gel-holder, so that the paper could touch the bottom of the tray, and absorb the 
buffer in the tray. It was carefully soaked with 10X SSPE. The inverted gel was placed on the 
Whatman paper, avoiding the air bubbles between the gel and the paper. A Hybond N-plus membrane 
was cut to the same size as the gel, one edge of the membrane was cut for marking the membrane. The 
4 side of the gel were surrounded with Parafilm. 2 pieces of 3MM paper were wetted in 2X SSC and 
placed on top of nitrocellulose membrane. Finally a pile of paper towels, just smaller than the 3MM 
papers was placed, and a glass plate was placed on top of the stack, and was weighted down with 500g 
weight on a glass plate on topof the blot-tower. The transfer of DNA was allowed to proceed for 20 
hours. The paper towels and the 3MM papers above the gel were removed. The gel side up was laid on 
a dry sheet of 3MM paper. The positions of the gel slots on the filter were marked with a pencil. The 
gel was peeled  
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Table.4. Primers and specifications of rpoB, rpsL genes and insertion element IS6110  
 
Sequence Tm Fragment length  
IS6110  
INS1 
INS2 
 
 
CGTGAGGGCATCGAGGTGGC 
GCGTAGGCGTCGGTGACAAA 
 
65°C 
 
 
123 bp 
rpoB gene 
TR 8 
TR 9 
 
TGCACGTCGCGGACCTCCA 
TCGCCGCGATCAAGGAGT 
 
58°C 
 
157 bp 
rpsL gene 
STR 52 
STR 34 
 
GTCAAGACCGCGGCTCTGAA 
TTCTTGACACCCTGCGTATC 
 
60°C 
 
272 bp 
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from the filter and stained for 10 min in a solution of EtBr (0.5 ug / ml ) in water, destained with water 
and examined by UV transilluminator for complete transfer of the DNA from the gel. The filter was 
soaked in 6X SSC for 5 min at room temp. to remove any piece of agrose sticking to the filter. Then the 
filter was removed from the 6X SSC and excess fluid was allowed to drain away. The filter was placed 
flat on a paper towel to dry for 30 min. The filter was sandwiched between two sheets of dry 3MM 
paper, and the DNA was fixed to the filter by baking for 1 hour at 80 oC in a vacuum oven. 
 
2.4.3.2.6 Preparation of DNA probe by PCR          
The PCR mixture was prepared using 2 ul of genomic DNA M. bovis BCG and INS1 and INS2. The 
amplified PCR products were checked by running on an agrose gel. 
 
2.4.3.2.7 Purification of the PCR product using geneclean-kit 
The PCR product was run on an 1% agrose gel in 1X TAE buffer. The band of the PCR product was 
excised, and weighted . 5 ul NaI were added to a solution of DNA, the NaI-agrose solution was 
incubated at 55 oC to melt gel for 5 min with occasional mixing by tapping. 5 ul of GLASSMILK 
suspensionwere added for the 5ug DNA purification. The DNA solution was incubated at room temp 
for 5 min to allow binding of the DNA to the silica matrix and was mixed every 2 min to ensure that 
GLASSMILK stayed suspended. The GLASSMILK /DNA complex was pelleted by spin in a 
microcentrifuge for 5 sec at full speed. The pellet was washed 3 times with new wash (40 volumes of 
the wash were added ), and the complex was resuspended by pipetting back and forth, after suspension, 
it was spinned for 5 sec in the centrifuge, and the supernatant was discarded, the wash procedure was 
repeated two more times. The pellet was dried by placing the tube under vacuum for 3 min. The then 
washed, white pellet was resuspended with water, TE and left for 5 min at room temperature, then 
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centrifuged for 3 min and carefully the supernatant containing the eluted DNAwas removed and placed 
in a new tube. 
 
2.4.3.2.8 Labeling the probe 
The probe was diluted with water from the ECL-kit (Amersham ) to a concentration of 10 ng / ul. The 
probe was then denatured for 5 min by placing it in a boiling waterbath, and chilled on ice immediately 
for 1 min. The probe mixture was spined a few seconds in a microcentrifuge at 12,000g, and an equal 
volume DNA labelling reagent was added, mixed well by pipetting. The same volume glutaraldehyde 
was added, mixed and carefully vortexed  for 1 second. The solution was spined a few seconds in a 
microcentrifuge at 12,000g and incubated for 10 min at 37 oC. The probe was then ready to use in a 
hybridization experiment. 
 
2.4.3.2.9 Hybridization 
The filter was prehybridized in a sealed plastic bag for 15 min at 42 oC. in hybridization buffer, which 
was poured in a bottle and the labeled probe was added, mixed well and poured back on the filter. That 
was hybridized overnight at 42 oC. under shaking. 
 
2.4.3.2.10 Washing the filter after Hybridization 
The primary wash buffer was pre-warmed to 42 oC . The filter was placed in a clean plastic box and 
washed twice with primary wash buffer for 20 min at 42 oC. 500 ml secondary wash buffer were added 
to the filter, the filter was washed for 5min at room temperature on a shaking platform, that wash was 
repeated twice. 
 
2.4.3.2.11 Detection 
Equal volumes of ECL detection reagent 1 and 2 were mixed in a bottle. The red light was turned on 
and the light was turned off. The filter was taken out of the secondary wash buffer, and excess fluid 
was drained, and moved to a clean plastic box. The detection mixture was poured directly on the blot 
on the DNA-side, and was evenly separated by rotating the box for exactly 1 min. the filter was taken 
from the box, drained and but onto a carrier and then warped in Saran warp and placed in a cassette 
with DNA side on top. The film twas place on the filter with the folded corner on the right top of the 
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filter. The cassette close one min, then the film replaced for a new exposure. The film was develop by 
the developer fot 5min and fixed. 
 
2.4.3.3 Gel electrophoresis 
2.4.3.3.1 Agarose gel electrophoresis 
The standard method for agrose gel electrophoresis 1.8% was described by Kolk et al (1992).  In this 
method 1.8% 1XTBE (Tris boric EDTA) agarose gel (1.8 agarose, 100ml of 1XTBE buffer) was 
poured in a horizontal electrophoresis apparatus. Ethidium bromide (EtBr) was added to the gel (5ul of 
10mg/ml EtBr per 100ml gel solution). The gel was covered with 1X TBE. 
Five microlitres of each PCR product were mixed with 3ul of loading buffer (glycerol, bromphenol 
blue and water ratio 1:1:8). A size marker DNA in the range 100-1000 bp (Boehringer Mannheim) was 
loaded for the determination of the amplified DNA size. The apparatus was connected to a power 
supply of a 80mA current for 30-45 mins. After completion of the run, the gel was observed under 
ultraviolet light to determine if PCR products have been successfully amplified. The bands size were 
estimated by base pair were depending on positive controls and the DNA marker. Negative controls 
were used to avoid contamination, sensitive controls used to avoid false positive results and positive 
controls consisted of resistant M. tuberculosis which were used to avoid false negative results and to 
compare them with the positive results.   Photography of the gel was performed by a Polaroid camera 
(Sigma) when needed.  
Controls: 
Mycobacterium tuberculosis strain H37Rv was kindly supplied by Dr. M. Hamid, Faculty of Veterinary 
Medecine, University of Khartoum and used as a sensitive positive control. Positive and negative 
controls of rpsL and rpoB were obtained from Stellenbosch University R.S.A. Negative control which 
included PCR mix without DNA, and DNA marker, were included in each run. 
 
2.4.3.3.2 Polyacrylamide gel electrophoresis (PAGE) 
The PAGE was prepared according to the procedure described by the IAEA protocol, (1999). 12% 
PAGE solution contains 30% acrylamide; 29g  acrylamide, 1g N,N,-methylene Bis-acrylamid, water to 
100ml),  3% ammonium persulphate; ( 0.3g Ammonium Persulphate, 10ml 
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water),  10X TBE; (108 g Tris, 55g boric acid, 7.4g EDTA), and 1000ml Water. PH8.30). Loading 
Buffer; (0.25% xylene cyanol, 30% glycerol) was used to visualize the DNA of M. tuberculosis 
complex. PAGE gel was stained with ethidium bromide (EtBr) for visualizing the amplified DNA 
fragments. The gel was left for one hour to set, then the molecular marker and the PCR product were 
loaded, I5 ul from each PCR product mixed with 3ul loading buffer and ran on PAGE gel for 
approximately 2 hour at 80 W in 1X TBE buffer, on vertical mini-gel apparatus. The results were 
viewed on transilluminator. 
2.5 Detection of mutations  
2.5.1Single Strand Confirmation Polymorphism (SSCP) 
The SSCP technique which depends on mobility shift was used to detect rpoB mutant genes. This 
process involves 6% PAGE (40ml from 30% acrylamid,4.2ml from 3% ammonium persulphate, 20ml 
from 6X TBE, 135ml water, 10ml glycerol,100µl TEMED) on vertical electrophoresis. The wells were 
cleaned by using a syringe and needle, pre-run for 10 min at  
50W was done on a cold place. 5µl of the PCR product was mixed with 5ul stop solution (95% 
formamide, 0.005% brom-phenol blue, 0.005% xyline cyanol, 20mM EDTA). The mixture was 
denatured at 95°C for 2 min, and immediately kept on ice, 10µl of samples and 5µl of marker was 
loaded onto gel, then electrophoresed at 50W in 0.6X TBE-buffer for 3 hours. The plate was then 
detached from the electrophoresis unit. 
 The PAGE gel stained by   silver stain as follows; the gel was fixed and shook gently for 8 min in 
solution 1( 0.5% acetic acid (5 ml), 10% ethanol (100ml), 895ml water) poured off and washed with 
water, then incubated for 10 min in salutation 2 (1g silver nitrate, 1000ml water) poured off and 
washed twice with water then incubated and shook gently in solution 3 (60ml sodium hydroxide; 45g 
sodium hydroxide, 300ml water ),  60ml sodium borohydrate; (0.3g sodium borohydrate, 300ml water), 
2.4ml formaldehyde, water up to 600), after that the reaction quenched by washing the gel in solution 4 
( 7.5g s STR52 and STR34 odium carbonate, 1000ml water) for 10 min.,Then the gel took to 
trnsimilator to looked for mobility shifts of bands in comparison to control samples and the marker. 
 
2.5.2 Restriction fragment length polymorphism (RFLP) 
RFLP was used to detect polymorphisms in rpsL gene using the restriction endonuclease Mob II. The 
set of primer STR52 and STR34 were used to amplify a 272 bp region of the rpsL gene (around codon 
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43). 10 µl PCR product was added to mixer content (Mob II enzyme 1µl (10U), 10X enzyme buffer 
2µl, water 7µl). The mixture was incubated at 37°C for 2 hours to activate the enzyme reaction, then 
the activity of the enzyme was stopped by incubating the mixer at 72oC for 10 min, after this steps 3µl 
loading buffer was added to each restricted product. The result was confirmed  on 12% PAGE on mini-
gel and visualized after staining with EtBr. In this particular case a mutation at codon 43 of the rpsL 
gene removes the Mob II cleavage site and isolates carrying the mutation at this position therefore 
remain undigested ( normal gene must cut- but mutant gene dose not cut). 
 
 
 
 
 
CHAPTER THREE 
RESULTS 
 
3.1Microscopic examination 
out of 250 suspected tuberculosis sputum samples 201 (80.4%) were found to be AFB following Ziehl 
Neelsen (ZN) stain and microscopic examination. samples were taken from suspected tuberculosis 
cases but these received on previous treatment (primary cases) 
3.2 Culture characterization 
All the 250 specimens were cultured on Löwinstein Jensen media at 37oC for at least 8 weeks using the 
pre-treatment methods. 147 (73.1%) out of the 201 specimens which were AFB positive, and three out 
of 49 which were negative AFB revealed growth of M. tuberculosis, the growth was obtained in more 
than two weeks with rough, dry colonies and cream colour without pigmentation. 17 (8.5%) were rapid 
grower mycobacteria (MOTT) which were not fully identified to species level. Four out of them were 
with yellow pigmentation. Seven of the strain revealed growth similar to Nocardia spp., whereas 14 
(6.9%) and 21(8.4 %) from which were AFB negative was contaminated plates and 16 (7.9%) from 
AFB positive and17 (6.8 %) which were AFB negative specimens did not show growth on LJ medium. 
These results are summarised in, table 5 and Fig. 2 exhibits the correlation of tuberculosis and other 
organisms among male (n=96= 38.4%) comparable to female (n=54=21.6%). Also the correlation of 
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tuberculosis and other organisms isolated from tuberculosis cases to BCG vaccination; 65 (26%) were 
vaccinated whereas 185 (74%) were not vaccinated, exhibits in (table 5 and Fig. 3). 
Table 6 and figure 4. Illustrates the comparison between microscopic and culture results 
3.3  DNA fingerprinting of  IS6110 
Results of Fingerprinting of  IS6110 analysis performed on culture is shown in (Fig. 5). 150 (60 %)  
IS6110- culture samples out of 250 culture samples were clasified as M. tuberculosis complex. The 
resistant strains to rifamipcin gave exactly match patterns and also five of the sensitive strains gave 
similar patterns too. While two sensitive strains revealed patterns with an extra band in one of them.  
 
 
 
Table 5.  
   Correlation of tuberculosis and other organisms isolated from tuberculosis cases to BCG 
vaccination and sex. 
 
BCG Sex No. of 
samples 
     Species 
vaccinated Not 
vaccinated 
female male 
150 (60 %)   M.  tuberculosis  9 (3.6%)  141(56.4%)  54(21.6%)  96 (38.4 %) 
17 (6.8 %) Rapid grower  12(4.8%)  5 (2%) 13 (5.2 %) 4 (1.4 %) 
7 (2.8 %) Nocardia sp.  3 (1.2%) 4 (1.6%) 2 (0.8%) 5 (2 %) 
8 (3.2 %) Fungi  7 (2.8%) 1 (0.4%) 6 (2.4%) 2 (0.8 %) 
  33 (13.2%) Contamination  19 (7.6%) 16 (6.4 %) 21(8.4%) 12 (4.8 %) 
35 (14%) No growth 15 (6%) 18 (7.2%) 15 (6%) 20 (8%) 
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      Table 6. Comparison between microscopy and culture results  
 
 
 
Microscopy M 
tuberculosis 
Fungi Nocardia 
sp. 
MOOT Contamination No growth
Positive AFB 
 
147 00 07 17 14 16 
Negative AFB 
 
03 08 00 00 21 17 
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 Figure 5 
DNA fingerprinting of IS6110 of M. tuberculosis isolates, digested by PVUII. 
Lanes 1 and 8 contain standardized DNA producing fragments of known molecular weights (Hae III), 
lanes 5,6 and 17 show few amount of DNA; patterns in lanes 4 and 7 match exactly (M. tuberculosis 
strains with rpoB mutant gene),  patterns in lanes 11 and15, and so patterns in lanes 8, 10, 12, 13 and 
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lane 16 of M. tuberculosis (sensitive strain)  patterns in lanes 2 and 3 match with exception of an extra 
band in lane 2,  lane 14 contain DNA of M. tuberculosis  with mutant types of rpsL gene, lane 9 contain 
DNA of  M. tuberculosis sensitive strain. 
 
       
 Figure. 6 
1.8 % agarose gel electrophoresis of PCR amplified rpoB gene (primers TR8 and  TR9) from M. 
tuberculosis isolates. 
 Lanes 1 and 19, rpsL negative control; lanes 2 and 16 positive controls; lanes 15 and 30 DNA marker 
(100 bp), lanes 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24,  25, 26, 27, 28 and 29 
clinical isolates of M. tuberculosis. 
 
 
 
 
 
 
1000bp 
 
 
300bp 
200bp 
100bp
 
1000bp    
 
 
300bp        
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Figure. 7 
Agarose gel electrophoresis of PCR amplified rpoB genes (157bp) from M.  tuberculosis isolates. 
Lanes 1, rpoB positive control; lane 3, negative control; lane 6, DNA marker (100 bp),   lanes 2, 4, 5, 7, 
8 9, 10, 11and 12 clinical isolates of M. tuberculosis. 
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Figure. 8 
6% polyacrymaide gel electrophoresis of PCR amplifide rpoB from M. tuberculosis isolates. 
Lanes 1, rpoB negative control; lane 7, rpoB positive control; lane 11, DNA marker (100bp), lanes 2, 3 
and 10 sensitive strains of M. tuberculosis; lanes 4, 6, 7 and 9 mutant rpoB genes showing mobility 
shift; lanes 5and show  a few mount of  DNA.  
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Figure. 9 
6% polyacrymaide gel electrophoresis of PCR amplifide rpoB from M. tuberclosis isolates. 
Lanes 1 rpoB negative control; lane 8 rpoB mutant gene control; DNA marker (100 pb) was used as 
molecular weight (not shown).  lanes 2, 3, 4, 5,7, 9, 12  and 13 sensitive strains of M. tuberculosis ; 
lanes 11  mutant rpoB genes showing mobility shift; lanes 6 and 10 show  a few mount of  DNA.  
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3.4 PCR –SSCP analysis of rpoB gene 
  
PCR was done to the 150 isolates which were AFB and showed typical morphological  characteristics 
of M. tuberculosis. The reaction was done using set of primers (TR8 and TR9) to amplify rpoB gene 
and were successfully amplified, (Fig. 7 and 8). 
 
SSCP of amplified rpoB gene, showed that 4 strains exhibited mobility shift of rpoB (strains; M.tb-
SD7, M.tb-SD44, M.tb-SD78 and M.tb-SD113). Out of 150 strains of M.  tuberculosis. (Table 7, 8 and 
Fig. 9, 10). 
 
3.5 PCR - RFLP analysis of rpsL gene 
PCR were done to the 150 isolates which were AFB and shown typical morphological characterization 
of M. tuberculosis, using set of primers (STR31 and STR51) to amplify rpsL gene, and were 
successfully amplified. (Table7, 8 and Fig. 11). 
 
By using Restriction Enzyme Mob II, two strains 1.3% (M.tb-SD78 and M.tb-SD205)out of 150, which 
were amplified, did not cut and that mean they contain rpsL mutant gene (Fig. 12 and 13). Only one 
strain (0.7%) showed mutations to both rpoB and rpsl genes (M.tb-SD78). (Table 7 and  8). 
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Figure 10 
Show a gorse gel electrophoresis of PCR amplified rpsL (272 bp) gene with primers STR52 and 
STR34 from M. tuberculosis isolates. 
1000bp 
900bp 
 
300bp  
200bp 
100bp 
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                     Lanes 1 rpsl positive control (DNA ready made) and lane 7 negative control; lane 4 DNA marker (100 
bp); lanes 2, 3, 4, 5, 6, and 8 clinical isolates of M. tuberculosis. 
  
Figure 11 
PCR – RLFP analysis of amplified rpsL gened digested with Mbo II restriction enzyme on 1 % agarose 
gel. 
Lanes 1and 9    DNA as molecular size marker (100 bp); lane 8 and 12, rpsl positive    control; and lane 
16, negative control; lane 14  and 15, rpsL mutant genes, lanes 2, 3, 4, 4, 6, 7,     10, 11, 12 and 13  M. 
tuberculosis isolates (no mutations). 
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Figure 12 
Restriction enzyme digest of rpsl gene 12% page gel electrophoresis analysis of the gene with 
restriction enzyme Mbo II.  
Lanes 1, rpsl positive control;  lane 2, rpsL negative control;  lanes 3 and 5 rpsL mutant types; lane  4, 
6, 7, 8, 9,  and 10 clinical isolates of M. tuberculosis (sensitive strains, no mutant genes). 
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    Table7. Drug resistance pattern and mutations to rpoB and rpsL genes among five M.               
     tuberculosis isolates  
Isolate Drug Pattern Mutations genes 
M. tuberculosis - SD7 rifampicin rpoB 531  
M. tuberculosis - SD44 rifampicin rpoB 531  
M. tuberculosis - SD78 rifampicin, streptomycin rpoB 531 &  rpsL 43 
M. tuberculosis - SD113 rifampicin rpoB 531  
M .tuberculosis- SD205 streptomycin 
 
rpsL 43 
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Table 8. Percent of drug resistant of mutations in rpoB and rpsL genes among 150 M. tuberculosis 
isolated from patient at Khartoum  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Mutant gene Number percent 
Rifampicin 
Streptomycin 
Mixed (Streptomycin & Rifampicin) 
rpoB gene 
rpsl gene 
rpoB & rpsl gene 
 
4 
 
2 
 
1                                 
2.7 % 
1.3 % 
0.7 % 
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CHAPTER FIVE 
DISCUSSION 
 
There has been a resurgence of interest in rapid diagnosis of M. tuberculosis infection following the 
increasing number of tuberculosis cases and outbreak of multi-drug resistant tuberculosis strains 
(MDR) over the past few years (Nolte  and Mitchock, 1995). 
The aims of the current study were to detect the primary drug resistance due to mutations in 
Mycobacterium tuberculosis to streptomycin and rifampicin, using molecular techniques as rapid and 
senstive methods and to estimate  the prevalence of mutant genes that are responsible for drug  
resistance of Mycobacterium tuberculosis. 
A total of 250 samples were studied; 201(80.5%) of the total were found to be acid fast baclii (AFB), 
this high percentage can be explained by the fact that the all studied samples were already diagnosed as 
having AFB positive. 
150 out of the 250 were Mycobacterium tuberculosis complex (147 (73.1%) out of the 201 AFB 
positive gave growth of M. tuberculosis complex and three (6.1%) out of 49 which were AFB 
negative), 17 (8.5%) of the growth culture were rapid grower MOTTS, These results  was supported by 
the results done by Eldawi (2000) who found that  10% were acid fast bacilli other than tuberculosis, 
Included rapid growing mycobacteria.   
 Seven (3.5 %) were Nocardia spp. which was fully described and named Nocardia africana as a new 
species, and this results agree with the results of Sharaf Eldeen (2001), reported that 3.2% were 
Nocardia africana. 
 14 (6.9 %) were contaminated cultures and 16  (7.9%) were not grown. eight (16.3%) out of 49 of the 
samples were fungi.  
Although a presumptive diagnosis of pulmonary tuberculosis can be made on the basis of patients' 
histories and clinical and radiological findings, the definite bacteriological diagnosis of tuberculosis 
continues to depend on the microscopic examination of acid fast stained sputum smear acordding 
toWHO (1998). Direct microscopy with Ziehl Neelsen staining to identify acid fast bacilli is the most 
rapid method, but it lacks sufficient sensitivity and specificity as concluded in this study 150 (60%) out 
of 250 were M. tuberculosis, 17 (8.5%) out of 201 acid fast bacilli were MOTTs and 7(3.5%) were 
Nocardia sp., all can be judged AFB on microscope, by proceeding to more specific techniques such as 
culture , biochemical test and sequencing acordding to Miller et al., (1994) 
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The conventional bacteriological procedures used for the diagnosis of TB and detection of MDR in 
clinical laboratories either show poor sensitivity (microscopy) or time consuming (culture) which 
requires 4 - 8 weeks to isolate M. tuberculosis complex and the same time for sensitivity test 
(Horsburgh et al., 1986; Siddigi et al., 1985), this delayed diagnosis not only affects the treatment of 
the patient but may also lead to increasing of spread of MDR strains. For all above reasons the 
molecular techniques were used in this study, which decrease the required time to nearly half. 
The microscopic examination revealed the presence of AFB repeating the examination three times; 
only 60% of them were tuberculosis patients where as2.8% were pulmonary nocaridosic and10% were 
MOTT chest infections, this disagree with (WHO, 1996; Andrews and Radhakarishna, 1959 and 
Mitchison, 1968), which reported that it requiring at least two positive smears to classify a patient as 
having-sputum smear positive tuberculosis   
In this current study 17 (8.5%) out of 201 were rapid growers MOTTs, inspite of it was smear positive, 
but they show culture negative of TB. This result disagreed with Debrunner et al. (1992) and Maiko et 
al. (1994) who found that the efficiency of smear examination in detecting cases of tuberculosis 
subsequently shown to be culture positive and the high specificity of a positive sputum smear 
predicting M. tuberculosis is due to environmental mycobacteria which were supposed to be very rare 
(Chan et al., 1971).  
Seven strains (3.5%) were Nocardia sp. with similar symptoms to tuberculosis, this agreed with Wayne 
(1992) who noticed that there were some MOTTs and Nocardia spp. that can cause chest infections 
with similar symptoms to tuberculosis.  
14 (6.9%) of the culture bottles showed contamination and eight (3.2%) were fungi. This may be due to 
the decontamination method used in this study (4% NaOH), while by using 2%NaOH N- acetyl-L-
cystein which is described by Kubica et al. (1963) which is more effective but it is not recommended in 
drug resistance detections, so it was avoided in this study. 
16 (7.9%) showed no growth and that may be explained by the harsh decontamination procedures used 
(4% NaOH), or may be attributed to a few number of bacilli, or patients have been treated from other 
disease with streptomycin and / or rifampicin. 
Using molecular procedure such as polymerase chain reaction (PCR) IS6110, 150 out of 250 were 
confirmed to be M. tuberculosis complex. This results match with the culture results conducted in the 
current study. It is enforced by results of a previous study done by El Dawi (2000) which evaluated 
IS6110 for the diagnosis of tuberculosis in Sudan and concluded that PCR – amplified IS6110 
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increased the sensitivity to 88 % compared to 65% microscopy.   
DNA fingerprinting designated IS6110, first reported by Thierry et al., (1990) is usually used to 
identify M. tuberculosis complex. This ability to accurately identify related strains of M. tuberculosis 
complex can help to define the people and places involved in M. tuberculosis transmission.. However, 
in this study fingerprinting technique were used to confirm the results on strains, which have been 
microscopically and by culture classified as M. tuberculosis. 
M. tuberculosis DNA fingerprinting is based on small piece of repitive DNA, named IS6110, that may 
be present from 1 to 20 or more  times in the M. tuberculosis genome. Jan et al., (1993) noted that such 
data might provide impenitent insights into the global transmission of. M tuberculosis and identify 
strains with particular properties. The physical map of the IS6110 sequence indicates that various 
restriction enzyme cleaves within the 1,355- 6Pelment- Bam Ht, SstII, Pst I, BstEII, BssH II and PVU 
II have all been successfully used to generate restriction fragment length polymorphism (Zainuddin and 
Dale, 1988; Van et al., 1991; Cave et al., 1991 and Mazurek et al., 1991), but in this study PVUII was 
used as it has been used by the majority of laboratories and it cleaves 1S6110 sequence only once (Van 
et al., 1991). 
The use of conventional culturing methods in diagnosis and susceptibility testing of clinical isolates of 
M. tuberculosis is protracted, and can take up to 12 weeks before a prediction of a resistance pattern 
can be made. This has negative consequences for the treatment of infected individuals and can 
contributes towards the spread of MDR organisms according to Sinder et al., (1981); Siddgi et al. 
(1985) and Rastogi et al. (1989).  Thus, in this study, instead of culture detection for susceptibility 
testing of M. tuberculosis, more useful and rapid assays on nucleic acid amplification procedures such 
as single strand confirmation polymorphism (SSCP) and RFLP were used. 
Single strand confirmation polymorphism (SSCP) procedure was used in this study as previously 
described (Telenti et al. 1993). SSCP methods can detect mutations in 95 % of rifampicin - resistant 
clinical isolates of M. tuberculosis while sequencing can detect all mutations, but, the latter is too 
expensive. The basic cost per sample is more than 10 US $ and hand - on time eight hours, turn around 
time 48 hours and specific equipment needed cost approximately 100 000 – 120 000 US $, in 
sequencing. Whereas in manual SSCP the basic cost per sample is 1.75 $ and hand - on time 5.5 hours, 
turn around time less than 24 hours and specific equipment needed cost approximately 3 000 US $ 
according to Telenti and Persing (1996). SSCP is less demanding technique than sequencing; however 
automated SSCP would be best suited for reference laboratories serving a population with a high 
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prevalence of MDR tuberculosis. In contrast, SSCP using silver staining could represent a low cost 
option for other settings (Delgalo and Telenti, 1990). Therefore SSCP was used in this study. 
In this study four isolates (2.3%) were found to contain (rpoB) mutant genes that fall within the range 
0-3.0% and medium (0.2%) of WHO/ IUATLD (David et al., 1997). This result might not be exactly 
the real situation because mutations may be located outside of the region of analysis. In rifampicin-
resistant M. tuberculosis complex strains, resistance results from point mutations or from small 
deletions or insertions in a limited region of the gene encoding for the β-subunit of the RNA 
polymerase (rpoB). More than 30 different mutations have now been described in a region spanning 81 
bP corresponding to a stretch of 27 amino acids (Kapur et al., 1995), hence could not be detected. If 
sequencing or INNO-LiPA were used, the percentage might be higher or accurate as concluded by 
Peggy et al. (1998).  
In Sudan Sharef eldeen (2001) found that the acquired resistance to rifampicin was 8% and it is more 
than the result of this study. 
A previous survey on drug resistance in the Western Cape indicated 10.8% and 4.2% for acquired 
resistance, and overall incidences of 6.8% and 2.4% (N=6 266) for INH and RMP respectively, when 
both initial and acquired resistance were taken into account. 
On the other side the rate of primary drugs resistance involved in this study was more than that detected 
by Robert et al., (2000), in France during surveillance of M. tuberculosis resistance (0.2%) from rpoB 
mutation gene mono-response in untreated patients. While the acquired resistance was higher (2.2%) 
which is similar to initial resistance result and as Robert et al (2000) concluded, there has been no 
increase in resistance to any drug among previously untreated patients.  
It has previously been shown that 90% of clinical isolates resistant to RMP have mutation in the rpoB 
gene Vareldzis et al. (1994). This allows the attractive opportunity of using this locus as a marker for 
rifampicin resistance. However, results from pervious studies were collectively obtained from both 
SSCP analysis and sequence data. Results from this study showed that by using a combination of two 
optimised SSCP procedures, it was possible to detect mutations in 95% of 20 rifampicin – resistant 
clinical isolates of M. tuberculosis. It is possible that the remaining 5% of the samples analysed, not 
showing SSCP mobility shifts with any of these two optimised procedures, might not be optimised for 
detection of some uncommon mutations. Other methods, such as dideoxy- fingerprinting (ddf) and 
denaturing gradient gel electrophoresis (DGGE) might assist in detection of these mutations. If present 
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for diagnostic purposes it is important to evaluate these procedures, since automated sequencing is not 
economical or practical for all institutions Williams et al (1994). 
The results of Vareldzis et al. (1994) suggest that it is not only possible to use mutations in the rpoB 
gene to predict rifampicin resistance but since there is a 95% chance that the particular organisms are 
also INH – resistant. This locus (rpoB) may also be used in the prediction of MDR strains. It was also 
shown in this study that conventional methods (culture) may be unnecessary, and that mutational 
screening can be done after short culture periods in BACTEC medium, or even directly from sputum 
samples. This may have immediate implications for the decision on chemotherapy, it is currently not 
feasible to test all tuberculosis cases, and it is recommended that only high -risk cases be selected.  
SSCP analysis allows the detection of single base changes in short DNA fragments due to mobility 
differences of single stranded DNA molecules. Since it was first used  by Orita et al. (1989),  in this 
study SSCP was used to detect primary resistant of M. tuberculosis to rifampicin  due to  mutation in 
rpoB gene ( β - Subunit of the RNA polymerase). 
Other species of the genus Mycobacterium as M. leprae (Honore, et al., 1993. Guerrero, et al., 1994.) , 
M. avium (Williams, et al., 1994) and M. africanum  (Williams, et al. 1994 and Vareldzis et al. 
1994),were found to have the same mutations in the same gene but in different locations.  
PCR was used in this study to amplify the ribosomal protein S12 (rpsL gene) from M.    tuberculosis 
around codon 43 as most of the mutations associated with streptomycin resistance involve this gene 
according to Finken, et al. (1993) who used PCR to amplify encoding 16S rRNA and the ribosomal 
protein S12 from M .tuberculosis and concluded that in total of 38 STR –resistant 29 had mutations; in 
rrs (n=9=31%) or rpsL (n=20=69%). The 20 strains with rpsL gene mutations had variant codons for 
amino acids 43 (n=14=70%) and 88 (n=6=30%). All mutations observed in the rpsL gene resulted in 
either Lys?Arg or Lys?Thr substitutions.  
In the current study streptomycin resistance found to be 1.3% which lies within the WHO/ IUATLD 
range 0.1% – 23.5 %, but less than the medium (3.5%) (David et al., 1997). This can be explained by 
the fact that the mutant gene (rrs gene) was not detected in this study.  Moreover, the ribosomal protein 
S12 rpsL related mutations were only detected around codon 43 and those around codon 88 were not 
included in this study.  
Other studies detected streptomycin resistance; in Ethiopia (1987) (Lemma et al. 1989); Kenya (Githui 
et al. 1993) and Tanzania (WHO, 1995) who revealed approximately similar results to this current 
study which were , 1.9%, 0.8 - 1.8 %  and 0.3 - 1.0 % respectively. 
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Other studies done in Algeria ( Chaulet, 1993) and Kenya ( Githui et al., 1992) showed less        
prevalence: 0.9 and 0.8 respectively. 
In contrast to other studies done in Sudan Sharef Eldeen (2001); Libya ( Elghoul et al. 1989); South 
Africa – Western Cape ( Weyer and Kleeberg, 1992); Mauritania (WHO/IUALTD, 1998) and Kalima- 
Zaire (1983-1986) by Caluwe (1989), who recorded higher ranges of resistance prevalence 30%, 7.8-
6.8%, 12.1%, 17.5% and 23.5% respectively. 
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CHAPTER SIX 
 
CONCLUTIONS AND RECOMMEDATION 
 
        CONCLUSIONS 
 
⇒ The present study concluded that, there were number of primary mutations associated with  
resistance to streptomycin and rifampicin. 
⇒ Using molecular methods, 3.9% of the studied strains were found to be resistant to anti-    
     tuberculosis drugs was 2.6% of them were rpoB mutant gene associated with rifampicin   
      resistance and 1.3% rpsl mutant gene associated with streptomycin resistance. 
⇒ The above mentioned may not reflect the actual incidence of resistance at study aria,  the 
reasons behind that could be; 
o The numbers of studied samples were not quite enough analytically to represent   
Khartoum State. 
o The study concentrated on mutations most frequently described, ignoring other 
mutations such as rpsL around codon 88 and rrs gene. 
⇒ It is unwise to depend only on microscopic examination for the diagnosis of tuberculosis since 
using other methods revealed that 3.5% of the samples were found to be Nocardia africana and 
8.5% were MOTT, which was previously identified microscopically as Mycobacterium 
tuberculosis. 
⇒ The PCR is more precise and less time consuming regarding the identification of 
Mycobacterium tuberculosis than other conventional methods. 
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      RECOMMEDATIONS 
 
⇒ The present study recommended for future works that, More studies are need for detecting 
primary drug – resistant, due to mutation to all frontline anti tuberculosis drugs in a large 
number of clinical isolates from more states of the Sudan. 
 
⇒ There is a need to rapidly and reliably diagnose of tuberculosis and to distinguish it from     
      MOTTS and Nocardia spp. Which are also causes of pulmonary infection. 
 
⇒ There is a need for rapid methods to detect resistant mutation not only to treat the patients early  
but also to reduce the spread of outbreak of multi – drug resistance tuberculosis. 
 
⇒ There is a need to correlate between primary and secondary drug resistance in order to know the 
transmission of commonly genes of drug resistance. 
 
⇒ The study recommended that, DNA fingerprinting need to be used to detect and distinguish  
between the species of Mycobacterium tuberculosis and other species, and to determine the 
transmission of cluster within Sudan and other neighbour countries.  
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Appendix 1 
 
Equipment: 
Analytical balance, automatic calibration                     Fisher scientific  
Block thermostat ( Analog Hot Block base )                     Boekel industries,inc 
Centrifuge              Hettich universal 11 
High power pack              Pharmaicia  
Horizantal Gel electrophoresis apparatus                     Biometra 
Incubator (Iso-temp )                                   Fisher scientific  
Low power pack P25                        Biometra 
Microcentrifuge              Roth, Chemikalien laborbedarf 
Micropepittes               Roth, Chemikalien laborbedarf 
Microscope  Olympus                       Olympus co. 
pH meter             Fisher brand 
Polaroid gel camera                       Sigma 
Safety cabinet class II for culture                   Heraeus instruments 
Safety cabinet for PCR mixture           M J Research 
Sequencing apparatus model 377                      Perkin Elmer 
Stirrer, magnetic, with hot plate Alminum                     Fisher scientific UK  
Thermal cycler             Biometra 
Transilluminator             Biometra  
Ultra violet protective eyes glass            Nycomed Amersham 
Ultra violet protective face shields           Nycomed Amersham 
Vortex mixer              Fisher scientific 
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Appendix 2 
 
Materials 
Aerosol barrier tips                        Sigma   
Glass microslides with cut edges             Superior - German  
Clinical Autoclave            Labsco 
Disposable sterilized Eppendorf tubes                              Sigma 
          (1.5-0.5 ml)  
Polaroid film                        Labsco  
Plastic disposable Conical tubes 15-50ml                   Falcon . 
Plastic disposable pipettes           Roth, Chemikalien laborbedarf  
Sputum container            Vderman International  
 
Appendix 3     
    Chemicals and Reagents 
Acetic acid              Sigma  
Agarose       Mresco Agarose, Biotechnology 
Ammonium persulphate             Sigma   
   Bis-Acrylamide .              Sigma 
Boric acid               Sigma  
Bovine serum albumin fraction V            Promega   
Bromo-phenol blue              Sigma  
Carbol Fuchsin     BDH laboratory  
Deoxynucleotides (100mM )     Boehringer Mannheim 
EDTA                Sigma   
Acrylamide               Sigma   
Ethanol               Sigma   
Ethidium bromide              Sigma   
Glyserrol                          Sigma   
L - Asparagine              Sigma 
Maganesium chloride              Sigma 
Magnesium Chloride (100 mM )   Boehringer Mannheim 
Magnesium sulphate              Sigma 
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Malachite green     Aldrich chemiccal company, INC.  
Formaldehyde                         Sigma                                   Formamide                 
Sigma 
Methylene blue     BDH laboratory 
Oligonucleotides         Boehringer Mannheim 
10X PCR Reaction buffer        Boehringer Mannheim 
Phenol           BDH laboratory 
Polyvinyl pyrrolidone-360                       Sigma   
Potassium chloride                        Sigma 
Primers             (South Aftica) 
Silver nitrate                         Sigma 
Sodium Borohydride                        Sigma 
Sodium chloride                        Sigma  
Sodium citrate-N-acetyl-L-cystcine           Sigma 
Sodium deodcyle sulphate            Sigma 
Trisodium citrate hydrous            Sigma . 
Sodium hydrogen phosphate                       Sigma  
Sodium hydroxide             Sigma   
Sulfuric acid             BDH laboratory 
Taq polymerase            Boehringer Mannheim 
Tricene              Sigma   
Tris               Sigma   
Triton X              Sigma 
Xylene cyanol              Sigma 
  
     Ziehl Neelsen stain:- 
 
Solution A (Saturated alcoholic solution of fuchsin )  
         Basic fuchsin                                    3 g 
         Ethanol 96 %                                   100 ml 
 
Solution B (Phenol solution, 50g/L (5%) 
       Phenol crystals                                   10 g 
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       Water                                                                            200 ml 
       Solution A                                   10 ml 
       Solution B                                   90 ml 
 
 
Formula for decolorizing agent  
     Water, distilled if possible                                           300 ml 
      Sulfuric acid, concentrated                                100 ml  
 
Formula for counter staining Solution 
     Methylene blue                                  0.3 g 
     Water (distilled)                                             100 ml 
 
Löwenstein-Jensen medium:- 
 
Buffer salt solution       
     Potassium dihydrogen orthophosphate                     28 g 
     Disodium hydrogen orthophosphate                    16 g  
     Magnesium Sulphate                      1.6 g 
  Citric acid                        12 g 
      L-Asparagine                       40 g 
      Glycerol                    80 ml 
     Distilled water                  4 litres 
 
Complete medium  
     Buffer salt solution                            1200 ml 
     Whole egg                   2000 ml 
      1% Malachite green                  80 ml  
 
Appendix 4 
Molecular reagents  
10X Reaction buffer 
     500mM KCl 
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     100mM Tris 
     1% Triton 
Deoxynucleotides 
     100mM dATP, dCTP, dGTP, dTTP 
    Stock: 10µl of each of the above nucleotides up to 400 µl water 
   ( concentration = 2.5mM ) 
 
Magnesium chloride 
   100 mM 
   (Stock = 25mM) 
 
Taq polymrase  
    5U/µl 
Sets of  Primers 
    TR 8&TR 9 
   STR 52& STR 34 
    (Stock : 25mM solution) 
 
    Gel electrophoresis  
10XTBE 
     108g Tris 
     55g Boric Acid 
    7.4g EDTA 
  1000mL water: pH 8.30 
 
1.8%Agarose gel 
         1.8 g Agrose 
         100 ml 1X TBE buffer 
 
             Loading Buffer 
    0.25% Xylene cyanol 
   30% Glycerol 
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Ethidiumbromide  
 10mg/ml 
 
     Single strand conformation polymorphism (SSCP): - 
Acrylamide 30% 
   29g Acrylamide 
   1g Bis-Acrylamide 
   100mL water 
 
Ammonium persulphate 3% 
0.3g Ammonium persulphate 
10mL water 
 
Stop solution 
95% Formamide 
20mM EDTA 
0.005% Bromo- Phenol blue 
0.005% Xylene cyanol. 
 
 
6% page gel 
Distilled water                                135 ml 
30% Acrylamide                                40 ml 
6XTBE                                             20 ml 
3% Ammonium persulphate                                          4.2 ml 
Glycerol                                 10 ml 
TEMED                                 100µl 
 
   Silver staining procedure: - 
   Sodium hydroxide (stock) 
    45g sodium hydroxide 
    300mL water 
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  Sodium Borohydrate (stock) 
   0.3g sodium Borohydrate 
  300mL water 
 
Solution 1 
      100 ml Ethanol (10%) 
     5mL Acetic acid (0.5%) 
     895ml water 
 
      Solution 2 
   1g silver nitrate 
   1000 ml water 
 
Solution 3 
   60 ml sodium hydroxide (stock) 
   60 ml sodium Borohydrate (stock) 
   2.4 ml Formaldehyde 
   Water up to 600 ml 
 
Solution 4 
   7.5g sodium carbonate 
   1000 mL water 
   Solution 1 and 2 stable for ± 1 week 
   Solution 3 fresh as needed. 
 
   Restrection Fragment Length Polymorphisum 
PCR Product                                                                                 10 ul 
Enzyme  Mob II                                                                            1 ul 
10X enzyme buffer                                                                        2 ul 
water                                                                                              7 ul                       
Total                                                                                              20 ul 
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